

**ACYLATION AND STRUCTURAL
CHARACTERIZATION OF 5-(2,6-
DICHLOROBENZYL)-1,3,4-THIADIAZOLE-2-
AMINE**




**2018
MASTER'S THESIS
CHEMISTRY**

ALİ HASİN BAWAH

ACYLATION AND STRUCTURAL CHARACTERIZATION OF 5-(2,6-DICHLOROBENZYL)-1,3,4-THIADIAZOLE-2-AMINE

Ali Hasin BAWAH




**Karabük University
Institute of Science
Department of Chemistry
Master's Thesis**

KARABÜK

March 2018

I certify that in my opinion the thesis submitted by Ali Hasin BAWAH titled "ACYLATION AND STRUCTURAL CHARACTERIZATION OF 5-(2,6-DICHLOROBENZYL)-1,3,4-THIADIAZOLE-2-AMINE" is fully adequate in scope and in quality as a thesis for the degree of Master of Science.

Prof. Dr. Mustafa ER
Thesis Advisor, Department of Chemistry



This thesis is accepted by the examining committee with a unanimous vote in the Department of Chemistry as a master thesis. March 18, 2018

Examining Committee Members (Institutions)

Chairman: Prof. Dr. Mustafa ER (KBU)

Member: Assoc. Prof. Dr. Hakan TAHTACI (KBU)

Member: Assist. Prof. Dr. Tuncay KARAKURT (AEU)

Signature





.../.../2018

The degree of Master of Science by the thesis submitted is approved by the Administrative Board of the Graduate School of Natural and Applied Sciences, Karabük University.

Prof. Dr. Filiz ERSÖZ
Head of Graduate School of Natural and Applied Sciences.





“I declare that all the information within this thesis has been gathered and presented in accordance with academic regulations and ethical principles and I have according to the requirements of these regulations and principles cited all those which do not originate in this work as well.”

Ali Hasin BAWAH

ABSTRACT

M. Sc. Thesis

ACYLATION AND STRUCTURAL CHARACTERIZATION OF 5-(2,6-DICHLOROBENZYL)-1,3,4-THIADIAZOLE-2-AMINE

Ali Hasin BAWAH

Graduate School of Natural and Applied Sciences

The Department of Chemistry

Thesis Advisor:

Prof. Dr. Mustafa ER

March 2018, 91 pages

Thiadiazole is a five-membered heterocyclic aromatic compound containing two nitrogens and one sulfur heteroatoms. Its molecular formula is $C_2H_2N_2S$. Compounds containing thiadiazole are known to have special importance in heterocyclic chemistry as they possess biological activities. 1,3,4-thiadiazole and its derivatives have become the focus of attention in drug, agriculture and material chemistry due to their high activity in 2' and 5' positions against nucleophilic substitution reactions. The $-N=C-S$ group in the structure allows for great structural stability and is known to be the part responsible for biological activity. In addition to their anti-inflammatory, antidepressant, and antibacterial properties, thiadiazole derivatives are known to be effective against herbicides and fungicides.

Acetazolamide, an acyl derivative of 1,3,4-thiadiazole, has been widely used in medicine and in treatment of glaucoma, heart failure, and epilepsy. Researchers focus on possible new properties in hetero ring thanks to new compounds obtained by means of adding various substitute groups in thiadiazoles, which may contribute to medicine and industry. The main objective of this thesis is to carry out synthesis and characterization of new compounds containing substitute thiadiazole ring and their substitute acyl groups, which have potential biological activity. Firstly, 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (**2**) was synthesized with high yields. Then, the target compounds N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4,5-substitute benzamide derivatives (**4a-n**) were synthesized from reactions of these compounds with various acyl chloride derivatives with medium-high yields (76-91%).

The obtained compounds were characterized using IR, ¹³C-NMR, ¹H-NMR, MS, and Elemental Analysis.

Key Words : Thiadiazole, acylation, heterocyclic.

Science Code : 201.1.112

ÖZET

Yüksek Lisans Tezi

5-(2,6-DİKLOOROBENZİL)-1,3,4-TİYADİAZOL-2-AMİN BİLEŞİĞİNİN AÇILASYONU VE YAPISAL KARAKTERİZASYONU

Ali Hasin BAWAH

**Karabük Üniversitesi
Fen Bilimleri Enstitüsü
Kimya Anabilim Dalı**

**Tez Danışmanı:
Prof. Dr. Mustafa ER
Mart 2018, 91 sayfa**

Tiyadiazol, iki azot ve bir kükürt heteroatomu içeren, molekül formülü $C_2H_2N_2S$ olan beş üyeli heterosiklik aromatik bir bileşiktir. Tiyadiazol halkası içeren bileşikler heterosiklik kimyada önemli bir yere sahiptir. Bu bileşiklerin çeşitli biyolojik aktivite gösterdiği uzun yıllardır bilinmektedir. Nükleofilik süstitüsyon reaksiyonlarına karşı 2' ve 5' pozisyonları çok aktif olduğu için 1,3,4-tiyadiazol ve türevleri ilaç, tarım ve malzeme kimyasında son derece önem arz eden yapılar olarak son yıllarda ilgi odağı haline gelmiştir. Yapısında bulunan $-N=C-S$ grubu, yapıya büyük bir kararlılık sağlar ve biyolojik aktiviteden sorumlu olan kısım olarak bilinir. Tiyadiazol türevleri antienflammatuar, antidepresif, antibakteriyal özelliklerinin yanı sıra bazı türevlerinin herbisitlere ve fungusitlere karşıda etkin olduğu bilinmektedir. Tıp alanında yaygın olarak kullanılan asetazolamid, 1,3,4-tiyadiazolün açıl türevidir ve glakom, kalp yetmezliği ve epilepsi tedavisinde kullanılır. Bu özelliklerinden dolayı, çeşitli süstitüe gruplarının tiyadiazollere ilavesiyle, elde edilecek yeni bileşiklerin hetero halkaya sağlayacağı özelliklerden dolayı, tıp ve endüstri dünyasına

sağlanabilecek katkılar üzerinde çalışılmaktadır. Bu tezin ana amacı, potansiyel biyolojik aktiviteye sahip olan sübtitüe tiyadiazol halkası ve bunların sübtitüe açıl grupları içeren yeni bileşiklerin sentezi ve karakterizasyonudur. Bu amaç için, ilk olarak 5-(2,6-diklorobenzil)-1,3,4-tiyadiazol-2-amin (**2**) yüksek verimlerle (%88) sentezlendi. Ardından bu bileşiklerin çeşitli açıl klorür türevleriyle olan reaksiyonlarından orta-yüksek verimlerle (%76-91) hedef bileşikler N-(5-(2,6-diklorobenzil)-1,3,4-tiyadiazol-2-yl)-3,4,5-sübtitüe benzamid türevleri (**4a-n**) sentezlendi.

Sentezlenen bileşiklerin yapıları IR, ¹³C-NMR, ¹H-NMR, MS ve Elementel Analiz kullanılarak karakterize edilmiştir.

Anahtar Kelimeler : Tiyadiazol, açilleme, heterosiklik.

Bilim Kodu : 201.1.112

ACKNOWLEDGMENT

I would like to thank Prof. Dr. Mustafa ER, a faculty member of Department of Chemistry, Faculty of Science, Karabuk University, who provided his full attention and support for this thesis from its planning to execution, offered his knowledge and experiences, and placed this study on a scientific foundation with his guidance and help.

I'm highly grateful to the teachers of the chemistry department, who spent the time to offer me guidance. Also I would like to thank my family, my wife, my children, and all of my close friends. Finally, this thesis is dedicated to the soul of my mother and father.

CONTENTS

	<u>Page</u>
APPROVAL.....	ii
ABSTRACT.....	iv
ÖZET	vi
ACKNOWLEDGEMENT	viii
CONTENTS.....	ix
LIST OF FIGURES	xii
LIST OF TABLES	xviii
SYMBOLS AND ABBREVIATIONS INDEX	xix
PART 1	
INTRODUCTION	1
PART 2	5
GENERAL INFORMATION	5
2.1. THIADIAZOLES	5
2.1.1. Structure and Characteristics	5
2.1.2. Spectral Properties of 2-Amino-1,3,4-Thiadiazoles	6
2.1.2.1. IR Spectra.....	6
2.1.2.2. ¹ H-NMR Spectra.....	6
2.1.3. Methods Used to Obtain Thiadiazole	6
2.1.3.1. From Thiosemicarbazides	6
2.1.3.2. From Thiosemicarbazones	9
2.1.3.3. From Hydrazines.....	10
2.1.3.4. Other Methods	11
2.1.4. Significance of 1,3,4-Thiadiazole and Derivatives.....	14

	<u>Page</u>
PART 3	34
EXPERIMENTAL STUDIES.....	34
3.1. SYNTHESIS OF 2-AMINO-1,3,4-THIADIAZOLE DERIVATIVES	34
3.1.1. 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (2).....	35
3.2. GENERAL ACYLATION REACTIONS OF 2-AMINO-1,3,4- THIADIAZOLE DERIVATIVES (4a-n)	35
3.2.1. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)benzamide (4a)	35
3.2.2. N-(5-(2,6-dichlorobenzyl) -1,3,4-thiadiazole-2-yl) -4- nitrobenzamide (4b).....	36
3.2.3. N- (5- (2,6 -dichlorobenzyl)- 1,3,4-thiadiazole -2-yl) -4- (methylthio) benzamide (4c).....	36
3.2.4. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichlorobenzamide (4d).....	37
3.2.5. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluorobenzamide (4e)	37
3.2.6. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxybenz- amide (4f).....	37
3.2.7. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxybenz- amide (4g).	38
3.2.8. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluorobenzamide (4h).....	38
3.2.9. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichlorobenzamide (4i).....	39
3.2.10. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (4j).	39
3.2.11. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl) benzamide (4k)	39
3.2.12. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (4l).....	40
3.2.13. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (4m)	40
3.2.14. Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (4n)	40
 PART 4	 42
FINDINGS, DISUCSSION AND CONCLUSION	42
4.1. SYNTHESIS AND CHARACTERIZATION OF SOME NEW N-(5-(2,6- DICHLOROBENZYL)-1,3,4-THIADIAZOLE-2-YL)-3,4,5- SUBSTITUTED BENZAMIDE COMPOUNDS	42

	<u>Page</u>
ADDITIONAL EXPLANATIONS A COMPOUNDS' ^1H NMR SPECTRA.....	49
ADDITIONAL EXPLANATIONS B COMPOUNDS' ^{13}C NMR SPECTRA.....	58
ADDITIONAL EXPLANATIONS C COMPOUNDS' FT-IR SPECTRA.....	67
ADDITIONAL EXPLANATIONS D COMPOUNDS' MS SPECTRA.....	76
REFERENCES.....	85
CURRICULUM VITAE	91



LIST OF FIGURES

	<u>Page</u>
Figure 2.1. Thiadiazole isomers.....	5
Figure 2.2. Synthesis of 2-phenylamino-1,3,4-thiadiazole.....	6
Figure 2.3. Synthesis of 2-amino-5-substitute-1,3,4-thiadiazole from thiosemicarbazides	7
Figure 2.4. Synthesis of 2-norhydnocarpyl-5-amino-1,3,4-thiadiazole.....	7
Figure 2.5. Synthesis of ethyl-2-amino-1,3,4-thiadiazole-5-acetate/butyrate	7
Figure 2.6. Synthesis of 2-amino-5-aryl-1,3,4-thiadiazole.....	8
Figure 2.7. Synthesis 2,5-disubstituted-1,3,4-thiadiazole derivatives.	8
Figure 2.8. N-substituted-2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole derivatives.	8
Figure 2.9. 2-(2-Furoylamido)-5-aryloxymethyl-1,3,4-thiadiazole derivatives.....	9
Figure 2.10. 2-Amino-1,3,4-thiadiazole derivatives from oxidation cyclization catalyzed by ferric am	
Figure 2.11. Synthesis of 2-amino-5-substitute-1,3,4-thiadiazole	10
Figure 2.12.Synthesis of 2,4-dialkyl 1,3,4-thiadiazole from diacetyl hydrazines	10
Figure 2.13. Synthesis of 1,3,4-thiadiazole from hydrazine.....	10
Figure 2.14. Synthesis of 2-(4-aminophenyl)-5-alkyl/arylamino-1,3,4-thiadiazole ...	11
Figure 2.15. Synthesis of 1,3,4-thiadiazole derivatives.....	11
Figure 2.16. 2-Amino-5-phenyl-1,3,4-thiadiazole and 2-amino-5-phenyl-1,3,4-thiadiazole synthesis	
Figure 2.17. Synthesis of 2-aryl(heteroaryl)-5-phenylamino-1,3,4-thiadiazole	12
Figure 2.18. 1,3,4-Thiadiazole derivatives.....	13
Figure 2.19. Bis-(1,3,4-thiadiazole) derivatives	13
Figure 2.20. Some drugs containing 1,3,4-thiadiazole ring	14
Figure 2.21. 1,3,4-Thiadiazole derivatives obtained by Arun Kumar	15
Figure 2.22. 2-Aminoalkyl/aryl-5-(5-nitro)furan-1,3,4-thiadiazole derivatives	15

	<u>Page</u>
Figure 2.23. 5- Methyl-phenoxyethyl -2- [N- (2-alkyl -1,3,4- thiadiazole -5- yl) carbamoylmethyl-thio]-1,3,4-oxadiazole derivatives	16
Figure 2.24. 2-Amino-5-(1-methyl-5-nitro- <i>1H</i> -imidazole-2-yl)-1,3,4-thiadiazole....	16
Figure 2.25. 2-Amino-5-(1-methyl-2-nitro- <i>1H</i> -imidazole-5-yl)-1,3,4-thiadiazole....	16
Figure 2.26. 5-Arylamino-2-(4-aryl-2-methylthiazole-5-yl)-1,3,4-thiadiazole derivatives	17
Figure 2.27. 2-Amino/arylamino-[3,5-dimethyl-1-4-nitrophenyl] <i>1H</i> -pyrazole-yl] methylene-1,3,4-thiadiazole derivatives	17
Figure 2.28. 2-[(3-Ethyl-4-(3 <i>H</i>)quinazolinone-2-yl)mercaptomethyl-5-alkyl/arylamino -1,3,4-thiadiazole derivatives.....	18
Figure 2.29. 2-Ethyl/benzyl-2-(2-amino-1,3,4-thiadiazole-5-yl)thiomethyl benzimidazole.....	18
Figure 2.30. 2-(Substitutedamino)-5-[4-(acetylamino)phenyl]-1,4-thiadiazole derivatives	18
Figure 2.31. 3-(5-Anilino-1,3,4-thiadiazole-2-yl)-2-methyl-1,8-naphthyridine derivatives	19
Figure 2.32. 2-(4-Methoxybenzoylamino)-5-alkyl/arylamino-1,3,4-thiadiazole derivatives	19
Figure 2.33. 1-[(5-Substitutedamino-1,3,4-thiadiazole-2-yl)methyl]indol derivatives	19
Figure 2.34. 2-(4-Trifluoromethyl)acetamide-5-(3-hydroxy-2-naphthyl)-1,3,4-thiadiazole	20
Figure 2.35. 2-Acetylamino and 4-fluoro benzoylamino 1,3,4-thiadiazole derivatives	20
Figure 2.36. 2-Amino and 2-thione 1,3,4-thiadiazole derivatives	21
Figure 2.37. N-[2'-amino-(1''-acety -5- substituted -2''-pyrazoline-3''-yl)1',3',4',-thiadiazole-5'ilmethyl] anthranilic acid derivatives.....	21
Figure 2.38. Disubstituted 1,3,4-thiadiazole derivatives	22
Figure 2.39. 2,5-Disubstituted-1, 3, 4-thiadiazole derivatives	22
Figure 2.40. 2-Substituted-3-(1,3,4-thiadiazole-2-yl)thiazolidine-4-on derivatives..	23
Figure 2.41. 2-Ethylamino-5-(3-hydroxy-2-naphthyl)-1,3,4-thiadiazole derivative .	23
Figure 2.42. The 1,3,4-thiadiazole derivative synthesized by Masi Hasmin. H	24
Figure 2.43. 1,3,4-Thiadiazole derivatives containing alkylamino group in the 2-position	24
Figure 2.44. 2-Aryl-1,3,4-thiadiazole amide derivatives	25

	<u>Page</u>
Figure 2.45. 2-Aryl-5-hydrazine-1,3,4-thiadiazole derivatives	25
Figure 2.46. 2-Arylamino-1,3,4-thiadiazole derivatives	26
Figure 2.47. N-Phenyl-N-[4-(5-cyclohexylamino-1,3,4-thiadiazole-2-yl)phenyl] thiourea.....	26
Figure 2.48. N-phenyl-N-[4-(5-(4-fluorophenylamino)-1,3,4-thiadiazole-2-yl)phenyl] thiourea.....	26
Figure 2.49. A series of thiadiazole derivatives synthesized by Karigar Asif A. et al	27
Figure 2.50. The thiadiazole derivative designed by Prasanna A Datar et al	28
Figure 2.51. 2-Amino-5-(5'-aryloxy-1'-phenyl-4'-methoxy-pyrazole-3'-yl)1,3,4- thiadiazole derivatives	28
Figure 2.52 2-(4-Acetyl-aminobenzenesulphonamido)-5-(5'aryloxy-1'-phenyl-4'- methoxy-pyrazole-3'-yl)1,3,4-thiadiazole derivatives.....	28
Figure 2.53. 2-Aryl/pyridyl-5-alkyl/arylamino-1,3,4-thiadiazole derivatives	29
Figure 2.54. Thiadiazole derivatives designed by Arun Naskar et al	29
Figure 2.55. (<i>E,E</i>)-2,5-bis[4-(3-dimethylaminopropoxy)styryl]-1,3,4-thiadiazole....	30
Figure 2.56. Thiadiazole derivatives designed by Suddasatwa Banerjee et al.....	30
Figure 2.57. Thiadiazole derivatives containing acetyl and ethoxy carbonyl groups	31
Figure 2.58. 2-Amino-1,3,4-thiadiazole.....	31
Figure 2.59. 2-Formamide-1,3,4-thiadiazole	31
Figure 2.60. 2-Trifluoroacetamide-1,3,4-thiadiazole	32
Figure 2.61. 2-Arylamino-5-(4'-chlorophenylthiomethyl)-1,3,4-thiadiazole derivatives	32
Figure 2.62. 2-Acylamino-5-aryloxy-1,3,4-thiadiazole derivatives.....	32
Figure 2.63. 5-Substituted-2-(hexadecyloxypropionylamino)-1,3,4- thiadiazole derivatives.....	33
Figure 2.64. 5-Isopropylthio-2-(cyclohexyloxypropionylamino)-1,3, 4- thiadiazole	33
Figure 4.1. The synthetic pathway used to synthesize N-(5-(2,6-dichlorobenzyl)- 1,3,4-thiadiazole-2-yl)-3,4,5-substituted benzamide derivatives (4a-n). 42	42
Figure 4.2. Formation mechanism of 2-amino-1,3,4-thiadiazole derivative (2).....	43
Figure 4.3. Formation mechanism of the target compounds (4a-n)	44
Figure Annex A.1. ¹ H NMR spectra for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2- amine (2) compound (DMSO-d ₆)	50
Figure Annex A.2. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole- 2-yl) benzamide (4a) compound (DMSO-d ₆)	50

Figure Annex A.3. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (4b) compound (DMSO-d ₆).....	51
Figure Annex A.4. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio) benzamide (4c) compound (DMSO-d ₆).....	51
Figure Annex A.5. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichloro benzamide (4d) compound (DMSO-d ₆).....	52
Figure Annex A.6. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluoro benzamide (4e) compound (DMSO-d ₆).....	52
Figure Annex A.7. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (4f) compound (DMSO-d ₆).....	53
Figure Annex A.8. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (4g) compound (DMSO-d ₆).....	53
Figure Annex A.9. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluoro benzamide (4h) compound (DMSO-d ₆).....	54
Figure Annex A.10. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichloro benzamide (4i) compound (DMSO-d ₆).....	54
Figure Annex A.11. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (4j) compound (DMSO-d ₆).....	55
Figure Annex A.12. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl) benzamide (4k) compound (DMSO-d ₆).....	55
Figure Annex A.13. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (4l) compound (DMSO-d ₆).....	56
Figure Annex A.14. ¹ H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (4m) compound (DMSO-d ₆).....	56
Figure Annex A.15. ¹ H NMR spectra for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (4n) compound (DMSO-d ₆).....	57
Figure Annex B.1. ¹³ C NMR spectra for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (2) compound (DMSO-d ₆).....	59
Figure Annex B.2. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)benzamide (4a) compound (DMSO-d ₆).....	59
Figure Annex B.3. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (4b) compound (DMSO-d ₆).....	60
Figure Annex B.4. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio) benzamide (4c) compound (DMSO-d ₆).....	60
Figure Annex B.5. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichloro benzamide (4d) compound (DMSO-d ₆).....	61
Figure Annex B.6. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluoro benzamide (4e) compound (DMSO-d ₆).....	61
Figure Annex B.7. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (4f) compound (DMSO-d ₆).....	62

Figure Annex B.8. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (4g) compound (DMSO-d ₆).....	62
Figure Annex B.9. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluoro benzamide (4h) compound (DMSO-d ₆).....	63
Figure Annex B.10. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichloro benzamide (4i) compound (DMSO-d ₆)	63
Figure Annex B.11. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (4j) compound (DMSO-d ₆)	64
Figure Annex B.12. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl) benzamide (4k) compound (DMSO-d ₆)	64
Figure Annex B.13. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (4l) compound (DMSO-d ₆).....	65
Figure Annex B.14. ¹³ C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (4m) compound (DMSO-d ₆)	65
Figure Annex B.15. ¹³ C NMR spectra for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (4n) compound (DMSO-d ₆)	66
Figure Annex C.1. IR spectra for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (2) compound.....	68
Figure Annex C.2. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)benzamide (4a) compound.....	68
Figure Annex C.3. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (4b) compound.....	69
Figure Annex C.4. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio) benzamide (4c) compound	69
Figure Annex C.5. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichlorobenzamide (4d) compound	70
Figure Annex C.6. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluorobenzamide (4e) compound.....	70
Figure Annex C.7. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (4f) compound	71
Figure Annex C.8. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (4g) compound	71
Figure Annex C.9. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluorobenzamide (4h) compound	72
Figure Annex C.10. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichloro benzamide (4i) compound	72
Figure Annex C.11. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (4j) compound	73
Figure Annex C.12. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl) benzamide (4k) compound	73

Figure Annex C.13. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (4l) compound	74
Figure Annex C.14. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (4m) compound	74
Figure Annex C.15. IR spectra for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (4n) compound	75
Figure Annex D.1. Mass spectrum for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (2) compound	77
Figure Annex D.2. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)benzamide (4a) compound	77
Figure Annex D.3. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (4b) compound.....	78
Figure Annex D.4. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio) benzamide (4c) compound.....	78
Figure Annex D.5. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichlorobenzamide (4d) compound.....	79
Figure Annex D.6. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluorobenzamide (4e) compound.....	79
Figure Annex D.7. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (4f) compound.....	80
Figure Annex D.8. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (4g) compound.....	80
Figure Annex D.9. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluorobenzamide (4h) compound	81
Figure Annex D.10. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichloro benzamide (4i) compound.....	81
Figure Annex D.11. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (4j) compound.....	82
Figure Annex D.12. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl) benzamide (4k) compound.....	82
Figure Annex D.13. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (4l) compound	83
Figure Annex D.14. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (4m) compound.....	83
Figure Annex D.15. Mass spectrum for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (4n) compound.....	84

LIST OF TABLES

	<u>Page</u>
Tablo 1.1. Formulas Table.....	1



SYMBOLS AND ABBREVIATIONS INDEX

°C	: Centigrade
OH	: Hydroxyl
O	: Oxygen
N	: Nitrogen
H	: Hydrogen
S	: Sulfur
R	: Alkyl
C	: Carbon
Ar	: Aryl
EtOH	: Ethyl alcohol
H ₂ O	: Water
HCl	: Hydrochloric acid
P ₂ S ₅	: Phosphorus pentasulfide
H ₂ S	: Hydrogen sulfide
H ₂ SO ₄	: Sulfuric acid
CH ₃ OH	: Methyl alcohol
NH ₂ NH ₂	: Hydrazine
NaOH	: Sodium hydroxide
TFA	: Trifluoroacetic acid
DMF	: Dimethyl formamide
g	: Gram
ml	: Milliliter
CHCl ₃	: Chloroform
K ₂ CO ₃	: Potassium carbonate
cm	: Centimeter
ppm	: Parts per million
KBr	: Potassium bromide
DMSO	: Dimethyl sulfoxide

CDCl₃ : Deuterated chloroform
TMS : Trimethylsilane
D₂O : Deuterium oxide
Tyd : Thiadiazole
CF₃COOH : Trifluoroacetic acid

ABBREVIATIONS

NMR : Nuclear Magnetic Resonance
IR : Infrared
MS : Mass Spectrometry
DNA : Deoxyribonucleic acid
IUPAC : International Union of Pure and Applied Chemistry
HIV : Human Immunodeficiency Virus

PART 1

INTRODUCTION

Heterocyclic molecules are widespread in nature and are used in many fields. Among these, hetero ring compounds containing nitrogen and sulfur are known to have various biological activities. They have an important place in our live due to their biological activities. These compounds can be found in nature, but it is also possible to obtain them quickly and easily using synthetic methods, which increases their significance even more. In addition to pharmaceutics, these compounds are used in many other industries including the paint industry.

Thiadiazoles have an important place among compounds with hetero rings containing nitrogen and sulfur hetero and extensively used in pharmaceutics due to their biological activity. Fungicidal properties enabled by the $-N=C-S$ bond contribute to drug and paint industries in particular.

Schiff bases containing thiadiazole show high coupling properties and widely used in dyestuff synthesis. Also, such dyestuffs gain antibacterial properties without any further treatments as they contain thiadiazole ring. Moreover, Schiff bases obtained from 2,5-disubstitute-1,3,4-thiadiazoles have been found to show anti-inflammatory and antidepressant properties. Many studies show that some 1,3,4 thiadiazoles have antiallergic properties.

Furthermore, several thiadiazole derivatives are known to have extensive activities against fungicides and herbicides.

Various studies show that addition of different groups in the thiadiazole molecule lead to different biological activities.

1,3,4 thiadiazoles are also used in the polymer industry, which is one of the noteworthy industries of our time. Thermal behaviors of N and S atoms play a significant role in conductivity, hence 1,3,4 thiadiazoles are used for semi-conductivity and coating in polymer applications with electrical conductivity.

Commonly used in medicine, acetazolamide is a derivative of 1,3,4-thiadiazole and used in treatment of glaucoma, heart failure, and epilepsy.

Acid solutions are used to remove rust in industrial processes. A controlled rust removing operation requires inhibitors. Sulfuric acid and hydrochloric acid are used to remove the oxide layer on steel and alloys containing iron. Most organic inhibitors cling on the metal surface by adsorption. Organic compounds containing sulfur, nitrogen, and oxygen atoms are widely used as acid inhibitors. Thiadiazoles are known to be commonly used as such inhibitors.

For the reasons mentioned above, researchers focus on possible new properties in hetero ring enabled by new compounds obtained by means of adding various substitute groups in thiadiazoles, which may contribute to medicine and industry.

Overall, this thesis consists of two parts: a literature review and experimental trials. These two sections are also divided into sub-sections. Structure formulas of compounds synthesized in experimental trials can be seen in the Table of Formulas.

The second part of the study presents general information related to thiadiazole and derivatives, earlier and recent studies, and synthesis methods based on a review of the literature.

The third part of the study involving experimental trials explains how 2-amino-1,3,4-thiadiazole compounds were obtained from reactions of appropriate nitrile compounds with thiosemicarbazide, and acylation reactions of these compounds.


Since the yield calculation for synthesized compounds was performed after the purification process, yields are given as pure yield.

The four part involving experimental results and discussion presents the spectral data for all compounds in charts and interprets the data based on literature data.


The fifth section containing the results presents reactions mechanisms for synthesized compounds in equations.




Table 1.1. Formulas Table




1




2




4a




4b




4c




4d




4e




4f




4g




4h




4i




4j




4k



4l



4m



4n

PART 2

GENERAL INFORMATION

2.1. THIADIAZOLES

2.1.1. Structure and Characteristics

Heterocyclic compounds are known to involve one or more heteroatoms other than carbon and hydrogen such as oxygen, nitrogen, or sulfur and have the maximum number of conjugated double bonds. Systems containing two nitrogen atoms and one sulfur atom in a five-membered heterocyclic ring are referred to as thiadiazole ring in Hantzsch-Windman nomenclature. Thiadiazole has four isomers depending on the position of heteroatom in the ring: 1,2,3-thiadiazole(1), 1,2,4-thiadiazole(2), 1,2,5-thiadiazole(3), and 1,3,4-thiadiazole(4).



Figure 2.1. Thiadiazole isomers.

1,3,4-thiadiazole is a colorless substance with aromatic character. It has a melting point of 45 °C and boiling point of 203 °C. It is quite resistant against acids. It can be decomposed in 30% hydrogen peroxide and diluted alkaline zinc.

We will mostly address 2-amino-1,3,4-thiadiazole derivatives in detail in this study.

2.1.2. Spectral Properties of 2-Amino-1,3,4-Thiadiazoles

2.1.2.1. IR Spectra

IR spectroscopy using KBr tablets in studies on 2-amino-1,3,4-thiadiazole derivatives show absorption bands for C=N stretching vibration in the 1665-1672 cm^{-1} range, C-N stretching vibration in the 1300-1280 cm^{-1} range, N-H deflection in the 1620-1600 cm^{-1} range, and amino group N-H stretching vibration in the 3350-3100 cm^{-1} range [1].

2.1.2.2. $^1\text{H-NMR}$ Spectra

According to the structure of the substituents at the amino nitrogen of 2-amino-1,3,4-thiadiazoles, $^1\text{H-NMR}$ spectra of the protons in secondary amine are in the 10.20-10.30 ppm range [2].

2.1.3. Methods Used to Obtain Thiadiazole

The first compound known to contain a 1,3,4-thiadiazole ring is the 2-phenylamino-1,3,4-thiadiazole compound synthesized by Pulvermacher in 1894 by formic acid treatment of 4-phenyl-thiosemicarbazide [3].




Figure 2.2. Synthesis of 2-phenylamino-1,3,4-thiadiazole

2.1.3.1. From Thiosemicarbazides

1,3,4-thiadiazoles are usually formed as a result of cyclization reactions. Many syntheses of thiadiazoles occur in the form of cyclization reaction of thiosemicarbazide or substitute thiosemicarbazide.

2-amino-5-substitute-1,3,4-thiadiazole is obtained as a result of cyclization from the reaction of thiosemicarbazide with acetyl chloride [4].




Figure 2.3. Synthesis of 2-amino-5-substitute-1,3,4-thiadiazole from thiosemicarbazides.

2-Amino-1,3,4-thiadiazole, 2-amino-5-phenyl-1,3,4-thiadiazole, and 2-phenylamino-5-phenyl-1,3,4-thiadiazole were synthesized by Freund and Meinecke (1896) and Markwald and Bott (1896) using the Pulvermacher's method (from thiosemicarbazides) [5,6].

Arnold synthesized 2-norhydnocarpyl-5-amino-1,3,4-thiadiazoles from the reaction of thiosemicarbazide with hydnocarpic acid chloride in 1942.




Figure 2.4. Synthesis of 2-norhydnocarpyl-5-amino-1,3,4-thiadiazole.

Clark et al. obtained ethyl-2-amino-1,3,4-thiadiazole-5-acetate/butyrate derivatives by heating thiosemicarbazides with carbethoxyacetyl/butyryl chloride in 1946 [7].




Figure 2.5. Synthesis of ethyl-2-amino-1,3,4-thiadiazole-5-acetate/butyrate.

In 1949, Hoggarth obtained 2-amino-5-aryl-1,3,4-thiadiazoles from the reaction of 1-(benzoyl/substitutedbenzoyl)thiosemicarbazides with phosphoric acid. Using

concentrated sulfuric acid instead of phosphoric acid to obtain this compound yielded the same result [8].




Figure 2.6. Synthesis of 2-amino-5-aryl-1,3,4-thiadiazole.

In 1973, Coburn and Bhoosman used a different method and obtained 2,5-disubstituted-1,3,4-thiadiazole from the reaction of thiosemicarbazide with orthoesters such as triethyl orthoformate and triethyl orthoacetate in media containing ethyl alcohol using acid as catalyst [9].




Figure 2.7. Synthesis 2,5-disubstituted-1,3,4-thiadiazole derivatives.

Doğan et al. (2002) obtained 1,3,4-thiadiazoles by adding sulfuric acid to thiosemicarbazide, stirring the reaction mixture in magnetic stirrer, transferring the mixture into iced water, and finally washing the mixture [10].

In 2006, Matsiak et al. synthesized N-substituted-2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole from the reaction of sulfinyl bis(2,4-dihydroxy)thiobenzoyl (STB) with 4-substituted-3-thiosemicarbazide [11].




Figure 2.8. N-substituted-2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole derivatives.

In 2001, Wang et al. synthesized 2-(2-furoylamido)-5-aryloxymethyl-1,3,4-thiadiazoles from the reaction of 1-aryloxymethyl-4-furoyl-thiosemicarbazides with glacial acetic acid using the microwave method, which allows for a quick synthesis with high yield [12].




Figure 2.9. 2-(2-furoylamido)-5-aryloxymethyl-1,3,4-thiadiazole derivatives.

1,3,4-thiadiazole was synthesized from the cyclization of thiosemicarbazides or oxidation cyclization of thiosemicarbazones catalyzed by ferric ammonia sulphate or ferric chloride [13].




Figure 2.10. 2-Amino-1,3,4-thiadiazole derivatives from oxidation cyclization catalyzed by ferric ammonia sulphate or ferric chloride.

2.1.3.2. From Thiosemicarbazones

In 1901, Compounds containing 1,3,4-thiadiazole ring from the reaction of thiosemicarbazones with iron(III) chloride were synthesised by Young and Eyre [14].




Figure 2.11. Synthesis of 2-amino-5-substitute-1,3,4-thiadiazole.

2.1.3.3. From hydrazines

Disubstituted-1,3,4-thiadiazoles are obtained from the reaction of diacetyl hydrazines with diphosphorus pentasulfide [15].




Figure 2.12. Synthesis of 2,4-dialkyl 1,3,4-thiadiazole from diacetyl hydrazines.

1,3,4-thiadiazoles are obtained from the reaction of hydrazine with sodium dithioformate [16].




Figure 2.13. Synthesis of 1,3,4-thiadiazole from hydrazine.

In 1985, Rollas synthesized 2-(4-aminophenyl)-5-alkyl/arylamino-1,3,4-thiadiazole derivatives for the first time from the reduction of 2-alkyl/arylamino-5-[p-(1-phenyl-3,5-dimethyl-4-(1*H*)-pyrazolyl-azo)phenyl]-1,3,4-thiadiazoles with hydrazinehydrate in ethyl alcohol medium without catalyst [17].




Figure 2.14. Synthesis of 2-(4-aminophenyl)-5-alkyl/arylamino-1,3,4-thiadiazole.

2.1.3.4. Other Methods

In 1961, Huisgen et al. obtained 1,3,4-thiadiazole derivatives by heating tetrazoles with electrophilic reagents such as isothiocyanate and thiocarboxylic acid chloride [18].




Figure 2.15. Synthesis of 1,3,4-thiadiazole derivatives.

In 1961, Kurzer synthesized N-thiobenzoaminoguanidine by treating aminoguanidine with carboxymethyl dithiobenzoate and obtained 2-amino-5-phenyl-1,3,4-thiadiazole

from its reaction with hydrochloric acid and 2-amino-5-phenyl-1,3,4-thiadiazole from its reaction with acetic anhydride [19].




Figure 2.16. 2-Amino-5-phenyl-1,3,4-thiadiazole and 2-amino-5-phenyl-1,3,4-thiadiazole synthesis.

In 2009, Efimova et al. obtained 2-aryl(heteroaryl)-5-phenylamino-1,3,4-thiadiazole derivatives from 5-aryl(heteroaryl)-tetrazoles and phenyl isothiocyanate with high yields using the microwave method [20].




Figure 2.17. Synthesis of 2-aryl(heteroaryl)-5-phenylamino-1,3,4-thiadiazole.

In 2009, El-Rahman et al. obtained 1,3,4-thiadiazole and bis(1,3,4-thiadiazole) derivatives under conventional and ultrasonic irradiation conditions by treating 1-methyl-5-oxo-3-phenyl-2-pyrazoline-4-thiocarboxyanilide with triethylamine, hydrogen halide, or N,N'-diphenyloxelo hydrazonile dichloride in ethyl alcohol medium [21].




Figure 2.18. 1,3,4-Thiadiazole derivatives.




Figure 2.19. Bis-(1,3,4-thiadiazole) derivatives.

2.1.4. Significance of 1,3,4-Thiadiazole and Derivatives

Biological activity of a compound essentially depends on its molecular structure. Heterocyclic compounds show high biological activity due to their structure. Thiadiazole having N=C-S structure in the ring is a versatile compound that can be used a wide range of applications. It has become a significant heterocyclic class due to its wide range of biological activities. Commercially available drugs containing 1,3,4-thiadiazole nucleus include acetazolamide, methazolamide, butazolamide, sulfamethazole, and megalol. Also, other analogs of thiadiazole are used for paints, pesticides, lubricants, and conductive polymers [22].




Figure 2.20. Some drugs containing 1,3,4-thiadiazole ring.

Rapidly developing resistance against available drugs has become a serious problem throughout the world. The need for designing new compounds to deal with this problem has become a priority in drug research in today's world. Thiadiazoles have been receiving constant attention from researchers for development of new drugs. In both pharmaceutical and agricultural chemistry, researchers have firmly established the importance of thiadiazole's biological properties. Studies in the literature have shown that compounds with thiadiazole nucleus have a broad spectrum of pharmacological activities including antimicrobial, antitubercular, anti-inflammatory, analgesic, CNS depressant, anticonvulsant, anticancer, antioxidant, antidiabetic, molluscicidal, antihypertensive, and diuretic activities.

Antimicrobial activity

Arun Kumar et al. demonstrated that the cyclization reaction of thiosemicarbazide with different aromatic carboxylic acids using POCl_3 yielded 1,3,4-thiadiazole. The resulting compounds were identified using elemental analysis, IR, $^1\text{H-NMR}$, and mass spectrum. The researchers found that the 1,3,4-thiadiazole derivatives had significant antimicrobial activities [23].




Figure 2.21. 1,3,4-thiadiazole derivatives obtained by Arun Kumar.

Sherman synthesized a series of nitrfurlylamino thiadiazole derivative derivatives and examined their antimicrobial activities. The researchers found that antimicrobial activity increased when phenylamino, ethylamino, and methylamino groups bonded to 1,3,4-thiadiazole ring, respectively [24].




Figure 2.22. 2-aminoalkyl/aryl-5-(5-nitro)furan-1,3,4-thiadiazole derivatives.

Mishra synthesized 5-substitutedphoxymethyl-2-[N-(2-alkyl-1,3,4-thiadiazole-5il)carbamoymethylthio] -1,3,4-oxadiazole derivatives and tested them for antimicrobial, insecticidal, and acetylcholine esterase inhibitor activities. The

derivative containing methyl at the 2-position of the 1,3,4-thiadiazole ring was found to be the most active compound for activities tested in the study [25].




Figure 2.23. 5-methyl-phenoxy-methyl-2-[N-(2-alkyl-1,3,4-thiadiazole-5-yl) carbamoyl methyl-thio]-1,3,4-oxadiazole derivatives.

Asato and Berkelhammer reported that, compared to 2-amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole, the corresponding 2-nitro isomer was inactive in terms of antibacterial activity [26].




Figure 2.24. 2-Amino-5-(1-methyl-5-nitro-1H-imidazole-2-yl)-1,3,4-thiadiazole.





Figure 2.25. 2-Amino-5-(1-methyl-2-nitro-1H-imidazole-5-yl)-1,3,4-thiadiazole.


Gawande and Shingare determined that 5-arylamino-2-(4-aryl-2-methylthiazole-5-yl)-1,3,4-thiadiazole derivatives showed antifungal activity against *Penicillium notatum* [27].



R₁: H, Br, Cl, CH₃, OCH₃ R₂: H, Br, Cl, OCH₃, OC₂H₅

Figure 2.26. 5-Arylamino-2-(4-aryl-2-methylthiazole-5-yl)-1,3,4-thiadiazole derivatives.


Patel and Fernandes obtained a series of compounds by binding [3,5-dimethyl-1-(4-nitrophenyl)-*lH*-pyrazole-yl]methylene to the 2- position of thiadiazole and found that the compound with amino group at 5-position was effective on *E. Coli*, while other compounds did not show any significant activity [28].



R: H, C₆H₅, 4-CH₃C₆H₄, 4-ClC₆H₄

Figure 2.27. 2-Amino/arylamino-[3,5-dimethyl-1-(4-nitrophenyl)-*lH*-pyrazole-yl]methylene-1,3,4-thiadiazole derivatives.


Terzioğlu et al. synthesized 2-[(3-ethyl-4-(3*H*)quinazolinone-2-yl)mercaptomethyl-5-alkyl/arylamino-1,3,4-thiadiazole derivatives and found that all compounds were inactive against bacteria and showed varying degrees of inhibition against fungi [29].



R: 4-Br/Cl/F/CH₃/NO₂C₆H₄

Figure 2.28. 2-[(3-ethyl-4-(3*H*)quinazolinone-2-yl)mercaptomethyl]-5-alkyl/aryl amino-1,3,4-thiadiazole derivatives.


Ashour et al. synthesized 1-ethyl or benzyl-2-(2-amino-1,3,4-thiadiazole-5-yl)thiomethyl benzimidazole derivatives and found that the compounds showed antimicrobial activity against *E. Coli* [30].



R: C₂H₅, CH₂C₆H₄

Figure 2.29. 2-Ethyl/benzyl-2-(2-amino-1,3,4-thiadiazole-5-yl)thiomethyl benzimidazole.


Gülerman et al. synthesized 2-(substitutedamino)-5-[4-(acetamino)phenyl]-1,4-thiadiazole derivatives. The derivative containing ethylamino at the 2-position of the thiadiazole ring was found to have a MIC value equal to that of tobramycin, which is used as a standard, against *M. Fortuitum* strain. The thiadiazole derivatives in the series were found to be inactive against *M. Tuberculosis*, and had lower antibacterial activity than antifungal activity [31].



R: H, CH₃, C₂H₅, C₃H₇, CH₂CH=CH₂, C₆H₅

Figure 2.30. 2-(Substitutedamino)-5-[4-(acetamino)phenyl]-1,4-thiadiazole derivatives.


Reddy et al. tested antifungal activities of 3-(5-anilino-1,3,4-thiadiazole-2-yl)-2-methyl-1,8-naphthyridine derivatives against *Fusarium Oxysporum* and *Drechslera Rostrata*, and found that the compounds had a minimum inhibitor concentration (MIC) of 100 and 500 mg/mL [32].



R: H, 4-Br, 4-CH₃, 3-CH₃O, 4-CH₃O

Figure 2.31. 3-(5-Anilino-1,3,4-thiadiazole-2-yl)-2-methyl-1,8-naphthyridine derivatives.


Rollas et al. synthesized 2-(4-methoxybenzoylamino)-5-alkyl/arylamino-1,3,4-thiadiazole derivatives, and found the compound containing cyclohexyl group was active against *Candida Albicans* ATCC 1021 [33].



R: CH₃, C₂H₅, C₃H₇, CH₂CH=CH₂, C₆H₁₁, C₆H₅

Figure 2.32. 2-(4-methoxybenzoylamino)-5-alkyl/arylamino-1,3,4-thiadiazole derivatives.

Tsotinis et al. synthesized 1-[(5-substitutedamino-1,3,4-thiadiazole-2-yl)methyl]indol derivatives, and found that the compound containing 1-naphthylamino at the 5-position showed antibacterial activity against *Straphylococcus Aureus* [34].



R: C₆H₅, 4-CH₃C₆H₄, 1-naftil

Figure 2.33. 1-[(5-substitutedamino-1,3,4-thiadiazole-2-yl)methyl]indol derivatives.

Doğan et al. obtained acetlythiadiazoles by acylating 2-(alkyl/arylamino)-5-(3-hydroxy-2-naphthyl)-1,3,4-thiadiazole derivatives with acetic anhydride, and found that the trifluoromethyl to be active against penicillin [10].




Figure 2.34. 2-(4-Trifluoromethyl)acetamide-5-(3-hydroxy-2-naphthyl)-1,3,4-thiadiazole.

Anti-inflammatory Activity

Non-steroidal anti-inflammatory drugs (NSAIDs) are known as important therapeutically active compounds that can be used to treat acute and chronic inflammation, pain, and fever.

In the survey literature, it was demonstrated that various heterocyclic compounds containing thiadiazole group have anti-inflammatory activity. Most of thiadiazole derivatives have anti-inflammatory activity.

Labanauskas et al. reported that 2-acetylamino and 4-fluoro benzoylamino derivatives of 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazoles had an anti-inflammatory activity equal to that of acety salicylic acid and ibuprofen, and lower toxicity compared to acety salicylic acid [35].




Figure 2.35. 2-Acetylamino and 4-fluoro benzoylamino 1,3,4-thiadiazole derivatives.

Mullican et al. synthesized a series of 1,3,4-thiadiazole derivatives, which were orally active and had non-ulcerogenic anti-inflammatory activity. Especially the derivatives with amino and thione at the 2-position were found to be orally active [36].




Figure 2.36. 2-Amino and 2-thione 1,3,4-thiadiazole derivatives.

Sharma et al. obtained anthranilic acid derivatives with 1,3,4-thiadiazole ring at the 2-position. Among the compounds synthesized, those containing phenyl group had 30% anti-inflammatory activity, while those containing 4-methoxyphenyl group had 40% anti-inflammatory effect. Also, the researchers found that the 3-methoxy-4-hydroxyphenyl group led to a considerable increase in anti-inflammatory activity, the 4-methoxy derivative was more active compared to the 3-methoxy derivative, and N-[2'-amino-(1''-acetyl-5-substituted-2''-pyrazoline-3''-yl)1',3',4',-thiadiazole-5'ylmethyl] anthranilic acid had higher anti-inflammatory activity compared to phenylbutazone [37].




Figure 2.37. N-[2'-amino-(1''-acetyl-5-substituted-2''-pyrazoline-3''-yl)1',3',4',-thiadiazole-5'ylmethyl] anthranilic acid derivatives.

Disubstituted thiadiazole derivatives were synthesized with the reaction between salicylic acid and thiosemicarbazide using concentrated H₂SO₄ by Shiv K. Gupta et al.. The researchers assessed in vivo anti-inflammatory activity, and found all

compounds to have moderate anti-inflammatory activity compared to the standard drug, ibuprofen [38].





Figure 2.38. Disubstituted 1,3,4-thiadiazole derivatives.

Anticonvulsant Activity

Epilepsy is a clinical picture which occurs as a result of temporary abnormal electrical discharges in the brain. The patient presents deficiencies in consciousness, behavior, movement, or perception functions for a clinically limited time period. The pharmacotherapy of epilepsy has been archived in the last ten years. In spite of the addition of new antiepileptic drugs to the clinical practice in the last twenty years, the maximal electroshock (MES) test and the subcutaneous pentylenetetrazole (scPTZ) test are the most commonly used animal models to characterize anticonvulsant activity in epilepsy.


Foroumadi et al. synthesized 2,5-disubstituted-1,3,4-thiadiazole derivatives with $-Cl$, $-NH_2$, $-SH$, $-SCH_3$ and $-SO_2CH_3$ groups at the 2-position and fluorophenyl group at the 5-position. In terms of the anticonvulsant activity of the compound containing fluorophenyl group at the 5-position, the fluorine atom was found to have no effect on the activity, while the derivatives containing amino group at the 2-position showed anticonvulsant activity [39].



R_1 : NH_3 , SH , SCH_3 , SO_2CH_3 X: 2-F, 3-F, 4-F

Figure 2.39. 2,5-Disubstituted-1, 3, 4-thiadiazole derivatives.

Chimmiri et al. synthesized a new series of 2-substituted-3-(1,3,4-thiadiazole-2-yl)thiazolidine-4-on derivatives and examined anticonvulsant activity of these compounds to find antiepileptic compounds with less side effects. The researchers found that the anticonvulsant activity when the fluorine atom was bonded to the 2-position and the 5-position of the phenyl ring [40].



R: H, SH R₁: C₂H₅, C₃H₇, C₆H₁₁, C₆H₅, 2-Br/Cl/F/OHC₆H₄, 3-ClC₆H₄, 4-ClC₆H₄, 3,4-Cl₂C₆H₃, 2,5-F₂C₆H₃, 4-C₆H₅-C₆H₄, 2-Cl-NO₂C₆H₃

Figure 2.40. 2-Substituted-3-(1,3,4-thiadiazole-2-yl)thiazolidine-4-on derivatives.

Doğan et al. synthesized 2,5-disubstituted-1,3,4-thiadiazole derivatives, and found that 2-ethylamino-5-(3-hydroxy-2-naphthyl)-1,3,4-thiadiazole had 90% more anticonvulsant activity compared to pentylenetetrazole and 80% more anticonvulsant activity compared to sodium valproate [10].




Figure 2.41. 2-Ethylamino-5-(3-hydroxy-2-naphthyl)-1,3,4-thiadiazole derivative.

Masi Hasmin. H et al. designed and synthesized a series of carboxamide derivatives with substituted 1,3,4-thiadiazole. The anticonvulsant activity of these compounds was assessed using the PTZ model (60 mg/kg) and the reference drug, carbamazepine (100 mg/kg). None of the compounds caused sedation as a side effect compared to the standard drug (carbamazepine). The researchers proved that such compounds were strong candidates for prospective anticonvulsant research [41].




Figure 2.42. The 1,3,4-thiadiazole derivative synthesized by Masi Hasmin. H.

Stilling et al. synthesized alkylamino derivatives with alkyl group instead of nitrogen at the 2-position, and investigated their anticonvulsant activity. The researcher determined that the aryl substitution or the elongation of the alkyl ring led to a decrease in anticonvulsant effect. Also, the biphenyl ring replaced by phenyl or benzyl at the 5-position of the thiadiazole ring led to a decrease as well [42].





Figure 2.43. 1,3,4-Thiadiazole derivatives containing alkylamino group in the 2-position.


Chapleo et al. synthesized 2-aryl-1,3,4-thiadiazole amide derivatives with 2-methylphenyl and 2-(trifluoromethyl)phenyl at the 5-position of the 1,3,4-thiadiazole ring, and examined their anticonvulsant activity. The authors found that the 2-(trifluoromethyl)phenyl derivatives were the most active, but showed side effects such as sedation and neurotoxicity [43].



R₁: H, CF₃, C₆H₅ R₂: H, CH₃, n-C₃H₇, C₆H₅CH₂ R₃: CH₃, C₆H₅ R₄: n-C₄H₉ R₅: H
 R₃: H, C₂H₅, n-C₄H₉, C₆H₅CH₂ R₄: H, C₂H₅

Figure 2.44. 2-Aryl-1,3,4-thiadiazole amide derivatives.

Chapleo et al. synthesized 2-aryl-5-hydrazine-1,3,4-thiadiazole derivatives, compared these to standard anticonvulsant drugs such as phenobarbital, carbamazepine, and phenytoin, and aimed to develop 5-(2-biphenyl)-2-(1-methylhydrazine)-1,3,4-thiadiazole as a new class of anticonvulsant agents. The researchers found these compounds to have antihypertensive effects. The derivatives containing chlorine, methyl, phenyl, and hexyloxy at the 2-position of the aromatic ring as a substituent were found to have high anticonvulsant activity, but low antihypertensive activity [44].



R: H, 2-Cl, 2-CH₃, 2-C₆H₅, 2-C₆H₁₁O R₁: H, CH₃, i-C₃H₇, n-C₄H₉, CH₂OCH₃, C₆H₅CH₂, C₆H₅CH₂CH₂
 R₂: H, CH₃, i-C₃H₇, c-C₅H₉, C₆H₅, CH(C₆H₅)₂ R₃: CH₃, i-C₃H₇, C₆H₅

Figure 2.45. 2-Aryl-5-hydrazine-1,3,4-thiadiazole derivatives.

Vio et al. synthesized 2-arylamino-1,3,4-thiadiazole derivatives, and found that the 2,6-dimethylphenylamino derivative had higher antihypertensive activity compared to the other compounds in the series. A decrease was observed in antihypertensive activity when the hydrogen at the 5-position of the thiadiazole ring was replaced with pyridyl group [45].




Figure 2.46. 2-arylamino-1,3,4-thiadiazole derivatives.

Antitubercular Activity

Tuberculosis is one of the oldest known infections and still poses a serious health risk throughout the world. It may affect lungs and several other systems. There is a high number of studies on the subject in the literature.

Karakuş and Rollas synthesized a series of N-phenyl-N-[4-(5-alkyl/arylamino-1,3,4-thiadiazole-2-yl)phenyl]thiourea derivatives, and found that the compound containing cyclohexyl had the highest antitubercular activity, whereas the derivative containing 2-fluorophenylamino had no antitubercular activity at all [46].




Figure 2.47. N-phenyl-N-[4-(5-cyclohexylamino-1,3,4-thiadiazole-2-yl)phenyl]thiourea.




Figure 2.48. N-phenyl-N-[4-(5-(4-fluorophenylamino)-1,3,4-thiadiazole-2-yl)phenyl]thiourea.

Karigar Asif A. et al. synthesized a series of thiadiazole derivatives. The structure of each compound was confirmed with FTIR.

The NMR and mass spectrum data and anti-tubercular activity against *Mycobacterium tuberculosis* were examined using microplate Alamar Blue Assay (MABA). All of the compounds showed good anti-tubercular activity [47].




Figure 2.49. A series of thiadiazole derivatives synthesized by Karigar Asif A. et al.

Antidiabetic Activity

Prasanna A Datar et al. designed thiadiazole derivatives as antidiabetic substances using the docking technique. The researchers synthesized these thiadiazole derivatives by microwave irradiation of the product in presence of aldehyde. The product itself was obtained from the cyclization of aromatic acid and thiosemicarbazide in presence of H₂SO₄. In vitro studies to assess antidiabetic activity were carried out using α -amylase inhibition and in vivo studies were carried out on alloxan induced diabetes rat model. Molecular docking revealed that synthesized derivatives and target proteins were actively involved in binding and had significant correlation with biological activity [48].






Figure 2.50. The thiadiazole derivative designed by Prasanna A Datar et al.

Hanna et al. synthesized a series of thiadiazole derivatives and found that 2-amino-5-(5'-arylo-1'-phenyl-4'-methoxy-pyrazole-3'-yl)1,3,4-thiadiazoles decreased blood glucose level by 15-16% and 2-(4-acetyl-aminobenzenesulphonamido) derivatives decreased blood glucose level by 18% [49].



Ar: 3-ClC₆H₄ Ar₁: 4-(CH₃)₂NC₆H₄, C₆H₅, 4-NO₂C₆H₄

Figure 2.51. 2-amino-5-(5'-arylo-1'-phenyl-4'-methoxy-pyrazole-3'-yl)1,3,4-thiadiazole derivatives.



Ar: 3-ClC₆H₄ Ar₁: 4-(CH₃)₂NC₆H₄, C₆H₅, 4-NO₂C₆H₄

Figure 2.52. 2-(4-acetyl-aminobenzenesulphonamido)-5-(5'-arylo-1'-phenyl-4'-methoxy-pyrazole-3'-yl)1,3,4-thiadiazole derivatives.

Mhasalkar et al. assessed hypoglycemic activity of 2-aryl/pyridyl-5-alkyl/arylamino-1,3,4-thiadiazole derivatives, and determined that the presence of 4-nitrophenyl, 4-pyridyl, and *p*-sulfamoylphenyl at the 2-position was necessary for hypoglycemic activity. Isopropylamino, phenylamino, and cyclohexylamino groups at the 5-position were also found to increase activity [50].




Figure 2.53. 2-aryl/pyridyl-5-alkyl/arylamino-1,3,4-thiadiazole derivatives.

Anticancer Activity

Arun Naskar et al. synthesized 2-amino-5-aryl-1,3,4-thiadiazole derivatives through oxidative cyclization of thiosemicarbazones using FeCl₃ as catalyst, and Schiff bases by concentrating these with aldehydes. The researchers assessed the anticancer activity of the derivatives using Ehrlich's ascites carcinoma cells, and all compounds presented significant anticancer activity [51].




Figure 2.54. Thiadiazole derivatives designed by Arun Naskar et al.

Chou et al. examined the human lung cancer cell A549 activity of (*E,E*)-2,5-bis[4-(3-dimethylaminopropoxy)styryl]-1,3,4-thiadiazole and found that the compound had anticancer activity [52].




Figure 2.55. (*E,E*)-2,5-bis[4-(3-dimethylaminopropoxy)styryl]-1,3,4-thiadiazole.

Suddasatwa Banerjee et al. synthesized thiadiazole derivatives by refluxing furan-2-carboxylic acid and thiosemicarbazide in presence of concentrated H_2SO_4 , and then reacted these compounds with various substituted aldehydes in presence of a few drops of acetic acid to prepare different Schiff bases. The researchers tested the compounds for *in vitro* anticancer activity on HT-29 colorectal cancer cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The compounds showed significant activity even in very low concentrations [53].




Figure 2.56. Thiadiazole derivatives designed by Suddasatwa Banerjee et al.

Sancak et al. synthesized 1,3,4-thiadiazole derivatives, and tested their growth inhibition properties on 3 human tumor cell lines, breast cancer (MCF7), non-small cell lung cancer (NCI-H460), and CNS (8SF-268). The researchers found that thiadiazole derivatives containing acetyl and ethoxy carbonyl groups had anticancer activity [54].




Figure 2.57. Thiadiazole derivatives containing acetyl and ethoxy carbonyl groups.

Miyamoto et al. synthesized 2-N and/or 5-substituted-2-amino-1,3,4-thiadiazole derivatives. Among the compounds synthesized, 2-amino-1,3,4-thiadiazole, 2-formamide-1,3,4-thiadiazole, and 2-trifluoroacetamido were found to have antitumor activity, whereas 5-substituted, 2-urethane, and 2-carbamate derivatives were found to be inactive [55].




Figure 2.58. 2-Amino-1,3,4-thiadiazole.




Figure 2.59. 2-Formamide-1,3,4-thiadiazole.





Figure 2.60. 2-Trifluoroacetamide-1,3,4-thiadiazole.


Bahadur et al. determined that 2-arylamino-5-(4'-chlorophenylthiomethyl)-1,3,4-thiadiazole derivatives showed antiviral activity against the virus of Ranikhet disease [56].



R: C₆H₅, 4-CH₃C₆H₄, 4-ClC₆H₄

Figure 2.61. 2-Arylamino-5-(4'-chlorophenylthiomethyl)-1,3,4-thiadiazole derivatives.

Mazzone et al. synthesized a series of 2-acylamino substituted thiadiazole derivatives. The researchers found that the local anesthetic effect of the derivative containing trialkoxyphenyl at the 5-position of the 1,3,4-thiadiazole ring was lower compared to dialkoxy derivatives. Also, 2-(3-piperidinopropionyl)amino-5-(3,4-methylenedioxy phenyl) and 2-(3-N-methylpiperazinopropionyl)amino-5-(3,5-dimethoxy-4-ethoxy phenyl)-1,3,4-thiadiazole had the highest local anesthetic effect compared to the standard substance, lidocain [57].




R: 3,4,5-(OCH₃)C₆H₂, 3,4-(OCH₂O)C₆H₃, 3,5-(OCH₃)-4-OC₂H₅C₆H₂
 X: Br, Cl n:1 R₁: H, CH₃, C₂H₅, C₆H₅ n:2,3 R₁: H

Figure 2.62. 2-Acylamino-5-aryloxy-1,3,4-thiadiazole derivatives.

Habib et al. investigated antihyperlipidemic and antihypercholesterolemic activities of 5-substituted-2-(hexadecyloxycarbonylpropionylamino)-1,3,4-thiadiazole and 5-

isopropylthio-2-(cyclohexyloxycarbonylpropionylamino)-1,3,4-thiadiazole derivatives, and found that the thiadiazole derivative containing isopropylthio group at the 5-position had antihyperlipidemic activity [58].



R: CH₃, C₆H₅, (CH₃)₂CHS

Figure 2.63. 5-Substituted-2-(hexadecyloxycarbonylpropionylamino)-1,3,4-thiadiazole derivatives.




Figure 2.64. 5-Isopropylthio-2-(cyclohexyloxycarbonylpropionylamino)-1,3,4-thiadiazole.

PART 3

EXPERIMENTAL STUDIES

This study was supported by the Scientific Research Fund of Karabük University (Project No: KBU-BAP-16/2-YL-090)

The ^1H -NMR and ^{13}C -NMR spectra of the compounds were assessed using an Agilent Annual Refill (400 MHz) device in the Central Research Laboratory of Recep Tayyip Erdoğan University. Mass spectrum was determined by the ESI (+) method using a Thermo TSQ Quantum Access device in the Central Research Laboratory of Recep Tayyip Erdoğan University. The elemental analysis of the compounds was performed using a LECO 932 CHNS (Leco-932, St. Joseph, MI, USA) device in the Central Research Laboratory of Recep Tayyip Erdoğan University. The melting points of the compounds were determined using a Thermo Scientific IA9000 device.

3.1. SYNTHESIS OF 2-AMINO-1,3,4-THIADIAZOLE DERIVATIVES (2)

The solution of the compound 1 (0.075 mol) in 40 ml trifluoroacetic acid is added thiosemicarbazide (0.100 mol) in a flask with a round bottom and then the mixture is heated at 60 °C for 4 hours on a condenser with the drying tube attached. At the end of 4 hours, the reaction mixture is poured on 200 ml ice-water mixture and neutralized with diluted ammonia. The resulting substance is filtered through a funnel. The solid substance obtained is rinsed with pure water, ethyl alcohol, and diethyl ether, respectively. Then, the substance is purified by crystallizing with an appropriate solvent or solvent mixture.

The pure substance is dried with P₂O₅ vacuum oven. Finally, structures of the synthesized compounds are illuminated with FT-IR, ¹H NMR, ¹³C NMR, mass spectroscopy, and elemental analysis.

The physical properties and the spectral data of the products are listed below.

3.1.1. 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-amine (2)

White solid, yield: 15.79 g (81%), m.p. 219-220 °C (DMF-EtOH, 1:15). IR (ATR, cm⁻¹): 3258-3098 (-NH₂), 3080 (Ar-CH), 2976 (Aliphatic CH), 1582 (C=N). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.40 (s, 2H, -CH₂), Arom-H [7.49 (d, *J*=8.0 Hz, 2H), 7.36 (t, *J*=8.0, 7.6 Hz, 1H)], 7.69 (bs, 2H, NH₂). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm): 32.16 (-CH₂), Arom-C [129.09 (CH), 130.49 (CH), 133.40 (C), 135.44 (C)], Thiadiazole-C [154.37 (C), 169.39 (C)]. *Anal.* Calcd. for C₉H₇Cl₂N₃S: C, 41.55; H, 2.71; N, 16.15. Found: C, 41.43; H, 2.76; N, 15.99. MS: *m/z* 260 (M⁺, 74); 261 (M+1, 51).

3.2. GENERAL ACYLATION REACTIONS OF 2-AMINO-1,3,4-THIA DIAZOLE DERIVATIVES (4a-n)

In a two-necked flask, compound (2) (0.004 mol) was suspended in dry benzene (40 mL) and pyridine (1 mL). Acyl chloride derivatives (0.004 mol) were added dropwise to this solution at room temperature with the assistance of a dropping funnel. The mixture was then refluxed and stirred for 4-6 h. The progress of the reaction was monitored by TLC at appropriate time intervals. After completion of the reaction, the solution was filtered and the solid matter was obtained. It was washed with deionized water, ethanol and diethyl ether, respectively. The solid matter was recrystallized from the appropriate solvent. All physical properties and spectral data derived from the obtained products are given in the Supplementary Material Section.

3.2.1. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)benzamide (4a)

White solid, yield: 1.14 g (78%), m.p. 279-280 °C (DMF-EtOH, 1:1). IR (ATR, cm⁻¹): 3169 (-NH-), 3061 (Ar-CH), 2983 (Aliphatic CH), 1667 (C=O), 1582 (C=N). ¹H

NMR (400 MHz, DMSO- d_6) δ (ppm): 4.62 (s, 2H, -CH₂), Arom-H [8.06 (d, $J=6.4$ Hz, 2H), 7.61 (d, $J=6.0$ Hz, 1H), 7.54 (bs, 2H), 7.52 (bs, 2H), 7.39 (t, 2H)], 12.99 (s, 1H, NH). ¹³C NMR (400 MHz, DMSO- d_6 , δ ppm): 31.80 (-CH₂), Arom-C [128.80 (CH), 129.08 (CH), 129.22 (CH), 130.64 (CH), 131.90 (CH), 133.41 (C), 134.64 (C), 135.52 (C)], Thiadiazole-C [159.86 (C), 160.84 (C)], 165.53 C=O. *Anal.* Calcd. for C₁₆H₁₁Cl₂N₃OS: C, 52.76; H, 3.04; N, 11.54. Found: C, 52.68; H, 3.00; N, 11.49. MS: m/z : 363.68 (M-1, 100), 365.85 (M+1, 84).

3.2.2. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-4-nitrobenzamide (4b)

White solid, yield: 1.21 g (74%), m.p. 320-321 °C (DMF-EtOH, 1:15). IR (ATR, cm⁻¹): 3133 (-NH-), 3044 (Ar-CH), 2930 (Aliphatic CH), 1677 (C=O), 1596 (C=N). ¹H NMR (400 MHz, DMSO- d_6) δ (ppm): 4.62 (s, 2H, -CH₂), Arom-H [8.39 (d, 4H), 7.54 (bs, 2H), 7.53 (bs, 2H), 7.39 (bs, 1H)], 13.40 (s, 1H, NH). ¹³C NMR (400 MHz, DMSO- d_6 , δ ppm): 31.80 (-CH₂), Arom-C [124.09 (CH), 126.64 (CH), 129.23 (CH), 130.41 (CH), 133.57 (C), 135.51 (C), 139.82 (C), 150.33 (C)], Thiadiazole-C [159.88 (C), 160.81 (C)], 165.40 C=O. *Anal.* Calcd. for C₁₆H₁₀Cl₂N₄O₃S: C, 46.96; H, 2.46; N, 13.69. Found: C, 46.88; H, 2.59; N, 13.56. MS: m/z : 408.93 (M⁺, 100), 410.96 (M+1, 93).

3.2.3. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-4-(methylthio)benzamide (4c)

White solid, yield: 1.13 g (69 %), m.p. 282-283 °C (DMF-EtOH, 1:1). IR (ATR, cm⁻¹): 3132 (-NH-), 3035 (Ar-CH), 2921 (Aliphatic CH), 1674 (C=O), 1595 (C=N). ¹H NMR (400 MHz, DMSO- d_6) δ (ppm): 2.48 (t, 3H, -CH₃), 4.61 (s, 2H, -CH₂), Arom-H [8.00 (d, $J=8.0$ Hz, 2H), 7.54 (d, $J=8.4$ Hz, 2H), 7.37 (m, 3H)], 12.90 (s, 1H, NH). ¹³C NMR (400 MHz, DMSO- d_6 , δ ppm): 14.95 (CH₃), 31.79 (-CH₂), Arom-C [125.32 (CH), 127.54 (CH), 129.22 (CH), 130.64 (CH), 133.66 (C), 135.52 (C), 139.63 (C), 145.70 (C)], Thiadiazole-C [160.46 (C), 163.66 (C)], 165.63 C=O. *Anal.* Calcd. for C₁₇H₁₃Cl₂N₃OS₂: C, 49.76; H, 3.19; N, 10.24. Found: C, 49.68; H, 3.06; N, 10.12. MS (ESI- m/z): 411,38 (M+1, 26), 413,34 (M+2, 48).

**3.2.4. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-3,4-dichlorobenzamide
(4d)**

White solid, yield: 1.25 g (73 %), m.p. 295-296 °C (DMF-EtOH, 1:15). IR (ATR, cm^{-1}): 3142 (-NH-), 3084 (Ar-CH), 2967 (Aliphatic CH), 1682(C=O), 1560 (C=N). ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 4.62 (s, 2H, -CH₂), Arom-H [8.30 (s, 1H), 7.99 (d, $J=8.0$ Hz, 1H), 7.80 (d, $J=8.4$ Hz, 1H), 7.53 (d, $J=8.0$ Hz, 2H), 7.38 (t, $J=8.0, 7.2$ Hz, 1H)], 13.15 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 31.84 (-CH₂), Arom-C [129.05 (CH), 129.22 (CH), 129.97 (CH), 130.68 (CH), 130.76 (CH), 131.42 (C), 131.98 (C), 133.54 (C), 135.51 (C), 136.16 (C)], Thiadiazole-C [159.85 (C), 160.96 (C)], 166.16 C=O. *Anal.* Calcd. for C₁₆H₉Cl₄N₃OS: C, 44.37; H, 2.09; N, 9.70. Found: C, 44.23; H, 2.01; N, 9.57. MS (ESI- m/z): 433.71 (M+1, 100).

**3.2.5. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-3,4-difluorobenzamide
(4e)**

White solid, yield: 1.30 g (80 %), m.p. 304-305 °C (DMF-EtOH, 1:15). IR (ATR, cm^{-1}): 3142 (-NH-), 3087 (Ar-CH), 2941 (Aliphatic CH), 1663 (C=O), 1563 (C=N). ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 4.61 (s, 2H, -CH₂), Arom-H [8.13 (t, 1H), 7.95 (s, 1H), 7.60 (q, 1H), 7.53 (d, $J=8.4$ Hz, 2H), 7.38 (t, $J=8.0, 8.0$ Hz, 1H)], 13.09 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 31.82 (-CH₂), Arom-C [118.32 (CH), 126.65 (CH), 129.21 (CH), 130.65 (CH), 133.54 (CH), 135.51 (C), 148.33(C), 150.91 (C), 151.47 (C), 154.11 (C)], Thiadiazole-C [159.80 (C), 161.90 (C)], 163.80 C=O. *Anal.* Calcd. for C₁₆H₉Cl₂F₂N₃OS: C, 48.02; H, 2.27; N, 10.50. Found: C, 48.11; H, 2.12; N, 10.36. MS (ESI- m/z): 400.00 (M⁺, 74), 402.26 (M+2, 54).

**3.2.6. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-3,4-dimethoxybenzamide
(4f)**

White solid, yield: 1.07 g (64 %), m.p. 252-253 °C (DMF-EtOH, 1:1). IR (ATR, cm^{-1}): 3155 (-NH-), 3047 (Ar-CH), 2941 (Aliphatic CH), 1661 (C=N), 1587 (C=N). ^1H

NMR (400 MHz, DMSO-d₆) δ (ppm): 3.82 (s, 6H, -OCH₃), 4.60 (s, 2H, -CH₂), Arom-H [7.71 (s, 2H), 7.52 (s, 2H), 7.37 (s, 1H), 7.08 (s, 1H)], 12.82 (s, 1H, NH). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm): 31.76 (-CH₂), 56.10 (-OCH₃), 56.17 (-OCH₃), Arom-C [111.59 (CH), 122.85 (CH), 123.66 (CH), 129.19 (CH), 130.59 (C), 133.68 (CH), 135.51 (C), 148.81 (C), 153.17 (C), 160.13 (C)], Thiadiazole-C [160.59 (C), 162.74 (C)], 164.73 C=O. *Anal.* Calcd. for C₁₈H₁₅Cl₂N₃O₃S: C, 50.95; H, 3.56; N, 9.90. Found: C, 50.78; H, 3.46; N, 9.78. MS (ESI-*m/z*): 423.91 (M⁺, 100), 425.87 (M+2, 66).

3.2.7. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-3,5-dimethoxybenzamide (4g)

White solid, yield: 1.00 g (59 %), m.p. 204-205 °C (DMF-EtOH, 1:1). IR (ATR, cm⁻¹): 3138 (-NH-), 3032 (Ar-CH), 2959 (Aliphatic CH), 1683 (C=O), 1596 (C=N). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 3.76 (s, 6H, -OCH₃), 4.39 (s, 2H, -CH₂), Arom-H [7.49 (d, *J*=8.0 Hz, 2H), 7.34 (t, *J*=8.0, 7.6 Hz, 1H), 7.04 (s, 2H), 6.71 (s, 1H)], 13.01 (bs, 1H, NH). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm): 31.76 (-CH₂), 56.09 (-OCH₃), 56.16 (-OCH₃), Arom-C [107.89 (CH), 109.73 (CH), 129.17 (CH), 130.59 (CH), 133.64 (C), 135.53 (C), 146.41 (C), 160.48 (C)], Thiadiazole-C [153.18 (C), 162.75 (C)], 164.33 C=O. *Anal.* Calcd. for C₁₈H₁₅Cl₂N₃O₃S: C, 50.95; H, 3.56; N, 9.90. Found: C, 50.79; H, 3.50; N, 9.81. MS (ESI-*m/z*): 423.91 (M⁺, 100).

3.2.8. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-3,5-difluorobenzamide (4h)

White solid, yield: 1.18 g (74%), m.p. 270-271 °C (DMF-EtOH, 1:1). IR (ATR, cm⁻¹): 3147 (-NH-), 3044 (Ar-CH), 2928 (Aliphatic CH), 1679 (C=O), 1595 (C=N). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.62 (s, 2H, -CH₂), Arom-H [7.76 (s, 2H), 7.54 (bd, 3H), 7.39 (t, 1H)], 13.16 (s, 1H, NH). ¹³C NMR (400 MHz, DMSO-d₆, δ ppm): 31.84 (-CH₂), Arom-C [108.80 (CH), 112.24 (CH), 112.43 (C), 129.22 (CH), 130.68 (CH), 133.51 (C), 135.51 (C), 163.80 (C)], Thiadiazole-C [161.35 (C), 161.48 (C)], 164.93 C=O. *Anal.* Calcd. for C₁₆H₉Cl₂F₂N₃OS: C, 48.02; H, 2.27; N,

10.50. Found: C, 47.96; H, 2.20; N, 10.56. MS (ESI-*m/z*): 399.80 (M-1, 100), 401.83 (M+1, 74).

3.2.9. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-3,5-dichlorobenzamide (4i)

White solid, yield: 1.33 g (77 %), m.p. 260-261 °C (DMF-EtOH, 1:1). IR (ATR, cm^{-1}): 3147 (-NH-), 3070 (Ar-CH), 2969 (Aliphatic CH), 1663 (C=O), 1563 (C=N). ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 4.62 (s, 2H, -CH₂), Arom-H [8.06 (s, 2H), 7.89 (s, 1H), 7.54 (d, $J=8.0$ Hz, 2H), 7.39 (t, $J=8.0, 7.6$ Hz, 1H)], 13.16 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 31.87 (-CH₂), Arom-C [127.60 (CH), 129.22 (CH), 130.69 (C), 132.50 (CH), 133.50 (C), 134.90 (C), 135.47 (C), 135.52 (C)], Thiadiazole-C [160.08 (C), 162.54 (C)], 163.93 C=O. *Anal.* Calcd. for C₁₆H₉Cl₄N₃OS: C, 44.37; H, 2.09; N, 9.70. Found: C, 44.22; H, 2.18; N, 9.52. MS (ESI-*m/z*): 431.79 (M-1, 56).

3.2.10. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-4-ethylbenzamide (4j)

White solid, yield: 1.02 g (65 %), m.p. 275-276 °C (DMF-EtOH, 1:1). IR (ATR, cm^{-1}): 3184(-NH-), 3059 (Ar-CH), 2964 (Aliphatic CH), 1662 (C=O), 1576 (C=N). ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 1.17 (t, 3H, -CH₃), 2.65 (q, 2H, -CH₂-), 4.61 (s, 2H, -CH₂), Arom-H [7.99 (d, $J=8.0$ Hz, 2H), 7.54 (d, $J=8.4$ Hz, 2H), 7.36 (m, 3H)], 12.87 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 15.61 (-CH₃), 28.58 (-CH₂-), 31.79 (-CH₂), Arom-C [128.47 (CH), 128.95 (CH), 129.01 (CH), 129.21 (CH), 130.62 (C), 133.66 (C), 135.52 (C), 149.83 (C)], Thiadiazole-C [159.65 (C), 160.72 (C)], 165.40 C=O. *Anal.* Calcd. for C₁₈H₁₅Cl₂N₃OS: C, 55.11; H, 3.85; N, 10.71. Found: C, 55.02; H, 3.79; N, 10.63. MS (ESI-*m/z*): 393.77 (M+1, 53).

3.2.11. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-4-(trifluoromethyl)benzamide (4k)

White solid, yield: 1.07 g (62 %), m.p. 274-275 °C (DMF-EtOH, 1:1). IR (ATR, cm^{-1}): 3152 (-NH-), 3041 (Ar-CH), 2943 (Aliphatic CH), 1680(C=O), 1531 (C=N). ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 4.63 (s, 2H, -CH₂), Arom-H [8.23 (d, $J=8.0$ Hz, 2H), 7.90 (d, $J=8.4$ Hz, 2H), 7.54 (d, $J=8.4$ Hz, 2H), 7.39 (t, $J=7.6, 7.6$ Hz, 1H)], 13.26 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 31.84 (-CH₂), 122.84 (CF₃), Arom-C [125.56 (CH), 125.99 (CH), 126.03 (CH), 129.22 (CH), 129.78 (C), 130.68 (C), 133.56 (C), 135.52 (C)], Thiadiazole-C [159.86 (C), 160.84 (C)], 165.53 C=O. *Anal.* Calcd. for C₁₇H₁₀Cl₂F₃N₃OS: C, 47.24; H, 2.33; N, 9.72. Found: C, 47.36; H, 2.26; N, 9.65. MS (ESI- m/z): 431.86 (M-1, 82).

3.2.12. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)-4-cyanobenzamide (4I)

White solid, yield: 1.26 g (81%), m.p. 334-335 °C (DMF-EtOH, 1:1). IR (ATR, cm^{-1}): 3142 (-NH-), 3094 (Ar-CH), 2921 (Aliphatic CH), 2235 (CN), 1684 (C=O), 1542 (C=N). ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 4.63 (s, 2H, -CH₂), Arom-H [8.18 (d, $J=8.4$ Hz, 2H), 8.01 (d, $J=8.0$ Hz, 2H), 7.54 (d, $J=8.4$ Hz, 2H), 7.38 (t, $J=8.0, 8.0$ Hz, 1H)], 13.27 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 31.86 (-CH₂), 118.56 (CN), Arom-C [115.40 (C), 125.54 (CH), 129.23 (CH), 129.61 (CH), 130.70 (CH), 133.03 (C), 133.53 (C), 135.52 (C)], Thiadiazole-C [159.88 (C), 160.86 (C)], 165.80 C=O. *Anal.* Calcd. for C₁₇H₁₀Cl₂N₄OS: C, 52.45; H, 2.59; N, 14.39. Found: C, 52.36; H, 2.46; N, 14.50. MS (ESI- m/z): 385.22 (M-4, 100).

3.2.13. N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-yl)acetamide (4m)

White solid, yield: 1.03 g (83%), m.p. 284-285 °C (DMF-EtOH, 1:15). IR (ATR, cm^{-1}): 3158 (-NH-), 3052 (Ar-CH), 2976 (Aliphatic CH), 1698 (C=O), 1563 (C=N). ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 2.12 (s, 3H, -CH₃), 4.56 (s, 2H, -CH₂), Arom-H [7.59 (d, $J=7.6$ Hz, 2H), 7.36 (t, $J=8.4, 8.0$ Hz, 1H)], 13.26 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 22.77 (CH₃), 31.75 (-CH₂), Arom-C [129.15 (CH), 130.56 (CH), 133.63 (C), 135.48 (C)], Thiadiazole-C [159.99 (C), 160.26 (C)], 169.01 C=O. *Anal.* Calcd. for C₁₁H₉Cl₂N₃OS: C, 43.72; H, 3.00; N, 13.91. Found: C, 43.76; H, 3.09; N, 13.86. MS (ESI- m/z): 302.01 (M⁺, 55).

3.2.14. Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazol-2-ylcarbamate (4n)

White solid, yield: 0.76 g (56%), m.p. 217-218 °C (DMF-EtOH, 1:5). IR (ATR, cm^{-1}): 3160 (-NH-), 3022 (Ar-CH), 2982 (Aliphatic CH), 1720 (C=O), 1569 (C=N). ^1H NMR (400 MHz, DMSO-d_6) δ (ppm): 1.23 (t, 3H, - CH_3), 4.17 (q, 2H, - OCH_2 -), 4.41 (s, 2H, - CH_2), Arom-H [7.51 (d, 2H), 7.36 (t, 1H)], 12.08 (s, 1H, NH). ^{13}C NMR (400 MHz, DMSO-d_6 , δ ppm): 14.65 (- CH_3), 27.00 (- CH_2 -), 62.60 (- OCH_2 -), Arom-C [129.20 (CH), 130.37 (CH), 133.83 (C), 135.42 (C)], Thiadiazole-C [160.63 (C), 161.48 (C)], 162.49 C=O. *Anal.* Calcd. for $\text{C}_{12}\text{H}_{11}\text{Cl}_2\text{N}_3\text{O}_2\text{S}$: C, 43.39; H, 3.34; N, 12.65. Found: C, 43.33; H, 3.36; N, 12.56. MS (ESI- m/z): 331.14 (M-1, 43).

PART 4

FINDINGS, DISCUSSION, AND CONCLUSION

4.1. SYNTHESIS AND CHARACTERIZATION OF SOME NEW N-(5-(2,6-DICHLOROBENZYL)-1,3,4-THIA DIAZOLE-2-YL)-3,4,5-SUBSTITUTED BENZAMIDE COMPOUNDS

In this study, the target compounds N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4,5-substituted benzamide derivatives (**4a-n**) were synthesized using the synthetic pathway shown in Figure 4.1.




Figure 4.1. The synthetic pathway used to synthesize N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4,5-substituted benzamide derivatives (**4a-n**).

In our study on synthesis and acylation of some new compounds containing 2-amino-1,3,4-thiadiazole ring, a total of 15 substances were synthesized, 1 recorded in the literature and 14 originals. 2-amino-1,3,4-thiadiazole derivatives and acylation reactions of these compounds were examined in this study, and 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (**2**) was obtained from the reaction of 2-(2,6-dichlorophenyl)acetonitrile (**1**) with thiosemicarbazide in TFA.

In this reaction, an addition occurs as a result of the thiosemicarbazide's nucleophilic attack on the positively charged iminium carbon, which forms under the catalytic effect of trifluoroacetic acid according to the literature data, from the hydrazine end, which is more basic. Although an intermediate stable product is not observed in the reaction, in parallel with the intermediate products observed in similar reactions, the elimination of the ammonia ion following the addition and then the nucleophilic attack of the sulfur atom on the carbon atom where the elimination occurs addition gives a 2-amino-1,3,4-thiadiazole derivative (**2**) as a result of heterocyclization [59].




Figure 4.2. Formation mechanism of 2-amino-1,3,4-thiadiazole derivative (**2**).

IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$ and MS spectra of the 2-amino-1,3,4-thiadiazole derivative (**2**) synthesized to illuminate its structure. The spectral data can be found in the experimental part of the article (Part 3) and relevant spectra can be seen in the Annotations section.

In the second part of our experimental trials, the target compound N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4,5-substituted benzamide derivatives (**4a-n**) were obtained from the reaction of 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (**2**) with substituted acyl derivatives (**3a-n**) in dry benzene accompanied by pyridine (Figure 4.1). The suggested reaction mechanism related to the formation of these compounds is shown in Figure 4.3.




Figure 4.3. Formation mechanism of the target compounds (**4a-n**).

This reaction is a typical nucleophilic acyl substitution reaction which occurs through nucleophilic addition to and elimination from the carbonyl group. Acyl compounds give displacement reactions as expected, because it is a group bonded to the carbonyl carbon and has sufficient ease of elimination (or turns into a group that eliminates well by protonation). Acyl chlorides usually give reactions by losing the chloride ion. The chloride ion is a very weak base and thus eliminates very well. Lone electron pairs on the nitrogen atom in the amino group of 2-amino-1,3,4-thiadiazole engage in nucleophilic attack on the acyl carbonyl as a nucleophile, and the carbonyl group in the sp^2 hybridized trigonal planar structure turns into a sp^3 hybridized tetrahedral structure with the opening of the double bond on the oxygen atom. Thus, the nucleophilic addition is completed. One of the protons in the amino group passes on to the chloride to facilitate the elimination. Then, the lone pair on the oxygen atom attacks the carbon atom to form a double bond, and eliminates together with hydrogen chloride bond electrons. Hydrogen chloride are kept as pyridinium chloride by pyridin, which is the weak base in the environment.

Structures of the target compounds (**4a-n**) were revealed with FT-IR, ^1H NMR, ^{13}C NMR, elemental analysis, and mass spectroscopy. The results can be found in the experimental part of the article (Part 3) and relevant spectra can be seen in the Annotations section.

All of the compounds synthesized were solid and the IR spectra of the original compounds were determined with ATR. ^1H -NMR spectra of the compounds synthesized were determined in DMSO-d_6 due to resolution problems. In ^1H -NMR spectra, methyl peaks due to DMSO-d_6 were approximately in the 2.50-2.60 ppm range, and water peaks were observed in the 3.20-3.40 ppm range. TMS used in deuterium solvents was taken as the standard chemical shift point in ^1H -NMR spectra.

The fact that 2-amino-1,3,4-thiadiazole derivative's (**2**) sharp absorption bands belonging to the $-\text{C}\equiv\text{N}$ group observed in the 2200-2250 cm^{-1} range in nitrile derivatives in IR spectrum disappeared and symmetric and asymmetric absorption

bands corresponding to the -NH_2 group emerged as two separate bands in the 3258-3098 cm^{-1} range shows that the ring was closed (cyclization).

The stretching band of the -C=N group in the thiadiazole ring was observed at 1582 cm^{-1} . Values for other azomethine stretching bands and aromatic aliphatic stretching bands of 2-amino-1,3,4-thiadiazole compounds and deformation bands of the aromatic ring can be seen in the experimental part.

The structure of the 2-amino-1,3,4-thiadiazole derivative (**2**) was confirmed with ^1H NMR spectroscopy as well. The -NH_2 group proton signals of compound **2** bonded to 1,3,4-thiadiazole ring from C-2 position in ^1H NMR spectra were recorded as a singlet corresponding to two protons in the 7.69 ppm range. Proton peaks belonging to the -NH_2 group of these compound (**2**) disappeared as a result of proton-deuterium exchange performed with D_2O . The methylene (-CH_2) protons bonding the phenyl group to the thiadiazole ring from the 5-position were observed as a singlet corresponding to 2 protons in the 4.40 ppm range. CH protons bonded to the phenyl ring were observed as a doublet corresponding to 2H-proton at 7.49 and a triplet corresponding to 1H-proton at 7.36. This is the most important evidence for the formation of compound **2**.

The structure of the 2-amino-1,3,4-thiadiazole derivative (**2**) was confirmed with ^{13}C NMR spectrum as well. The most significant data related to the formation of the 2-amino-1,3,4-thiadiazole ring is the similarity between ^{13}C -NMR data and resonance values of the carbons at thiadiazole C-2 and C-5 positions in these compounds and similar compounds [68]. C-2 carbon signals of the 2-amino-1,3,4-thiadiazole ring in these compounds were recorded at 154.37 ppm and C-5 carbon signals were recorded at 169.39 ppm. Other spectral data belonging to the carbon skeleton of the molecule fully support the suggested structures.

In the second part of our study, the target compounds (**4a-n**) were obtained from the reaction of acetylchloride with 2-amino-1,3,4-thiadiazole derivatives in presence of pyridine within dry benzene solvent.

In terms of IR spectrum values of these compounds, symmetrical and asymmetrical stretching bands corresponding to the -NH_2 group of the initial compound and observed at two separate bands at $3258\text{-}3098\text{ cm}^{-1}$ were replaced by -NH stretching bands observed at $3186\text{-}3121\text{ cm}^{-1}$, which is one of the most important evidences for the acylation of these compounds. Another evidence is C=O stretching band peaks observed at $1720\text{-}1661\text{ cm}^{-1}$ with the acylation of 2-amino-1,3,4-thiadiazole. The appearance of -NH and C=O stretching bands in IR spectra of compounds (**4a-n**) clearly shows that the amino group was acylated at the 2-position of 2-amino-1,3,4-thiadiazole. Peaks showing the bonding points of aromatic, aliphatic, azomethine, and substituted groups bonded to the aromatic ring can be seen in the experimental part.

Also, the $^1\text{H-NMR}$ spectrum data of the target compounds (**4a-n**) show that -NH_2 proton signals bonded to the 2-amino-1,3,4-thiadiazole ring at the C-2 position observed at 7.69 ppm disappeared.

Instead, the target compounds (**4a-n**) were observed as a singlet corresponding to a proton at 13.40-12.82 ppm indicating -NH signals, which is the most significant evidence for the acylation of 2-amino-1,3,4-thiadiazole (**2**) ring. This is consistent with the literature as well [59].

The peak of the 2-amino group observed at 7.69 ppm shifted to high values at 13.40-12.82 ppm due to electron attracting property of the carbonyl group, which is one of the considerable evidences for this structure. Other $^1\text{H NMR}$ spectrum data of these compounds is given in the experimental part of this study in detail.

C=O carbonyl group peaks are observed at 169.01-162.49 ppm in $^{13}\text{C NMR}$ spectrum of these compounds. The fact that this value was found in $^{13}\text{C NMR}$ spectrum is seen as an important evidence that the amino group at the 2-position of the thiadiazole ring was acylated. C-2 carbon peaks for the 1,3,4-thiadiazole ring in the target compounds (**4a-n**) were observed in the 159.65-161.47 ppm range, and C-5 carbon peaks were observed in the 160.72-163.66 ppm range. In these spectra, sp^3 hybridized S- CH_3 carbons appeared at 14.95 ppm in compound 4b, whereas -OCH_3

carbon peaks in compounds 4f and 4g resonated in the lower region due to the electronegativity of the oxygen atom and were observed in the 56.10-56.17 ppm range due to Sp^3 hybridized methylene carbons which bonds the thiadiazole ring to the aromatic ring in these compounds were observed in the 31.76-31.87 ppm range. These data belonging to the compounds are highly compatible with the literature.

The MS spectral data for compounds **2** and **4a-n** are as follows: 260 (M^+ , 74) and 261 ($M+1$, 51) for compound **2**, 363.68 ($M-1$, 100) and 365.85 ($M+1$, 84) for compound **4a**, 408.93 (M^+ , 100) and 410.96 ($M+1$, 93) for compound **4b**, 411,38 ($M+1$, 26) and 413,34 ($M+2$, 48) for compound **4c**, 433.71 ($M+1$, 100) for compound **4d**, 400.00 (M^+ , 74) and 402.26 ($M+2$, 54) for compound **4e**, 423.91 (M^+ , 100) and 425.87 ($M+2$, 66) for compound **4f**, 423.91 (M^+ , 100) for compound **4g**, 399.80 ($M-1$, 100), 401.83 ($M+1$, 74) for compound **4h**, 431.79 ($M-1$, 56) for compound **4i**, 393.77 ($M+1$, 53) for compound **4j**, 431.86 ($M-1$, 82) for compound **4k**, 431.86 ($M-1$, 82) for compound **4l**, 302.01 (M^+ , 55) for compound **4m** and 331.14 ($M-1$, 43) for compound **4n** which are compatible with the suggested structure.



**ADDITIONAL EXPLANATIONS A
COMPOUNDS' ^1H NMR SPECTRA**




Figure Annex A.1. ¹H NMR spectra for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (**2**) compound (DMSO-d₆)




Figure Annex A.2. ¹H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl) benzamide (**4a**) compound (DMSO-d₆).




Figure Annex A.3. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (**4b**) compound (DMSO- d_6)




Figure Annex A.4. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio)benzamide (**4c**) compound (DMSO- d_6).




Figure Annex A.5. ¹H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichloro benzamide (**4d**) compound (DMSO-d₆).




Figure Annex A.6. ¹H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluoro benzamide (**4e**) compound (DMSO-d₆).




Figure Annex A.7. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (**4f**) compound (DMSO- d_6).




Figure Annex A.8. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (**4g**) compound (DMSO- d_6).




Figure Annex A.9. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluorobenzamide (**4h**) compound (DMSO- d_6).




Figure Annex A.10. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichlorobenzamide (**4i**) compound (DMSO- d_6).




Figure Annex A.11. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (**4j**) compound (DMSO-d_6).




Figure Annex A.12. ^1H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl)benzamide (**4k**) compound (DMSO-d_6).




Figure Annex A.13. ¹H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (**4l**) compound (DMSO-d₆).




Figure Annex A.14. ¹H NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (**4m**) compound (DMSO-d₆).




Figure Annex A.15. ¹H NMR spectra for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (**4n**) compound (DMSO-d₆).



**ADDITIONAL EXPLANATIONS B
COMPOUNDS' ^{13}C NMR SPECTRA**




Figure Annex B.1. ^{13}C NMR spectra for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (**2**) compound (DMSO- d_6).




Figure Annex B.2. ^{13}C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)benzamide (**4a**) compound (DMSO- d_6).




Figure Annex B.3. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (**4b**) compound (DMSO-d₆).




Figure Annex B.4. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio) benzamide (**4c**) compound (DMSO-d₆).




Figure Annex B.5. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichloro benzamide (**4d**) compound (DMSO-d₆).




Figure Annex B.6. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluoro benzamide (**4e**) compound (DMSO-d₆).




Figure Annex B.7. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (**4f**) compound (DMSO-d₆).




Figure Annex B.8. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (**4g**) compound (DMSO-d₆).




Figure Annex B.9. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluorobenzamide (**4h**) compound (DMSO-d₆).




Figure Annex B.10. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichlorobenzamide (**4i**) compound (DMSO-d₆).




Figure Annex B.11. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (**4j**) compound (DMSO-d₆).




Figure Annex B.12. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl)benzamide (**4k**) compound (DMSO-d₆).




Figure Annex B.13. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (**4l**) compound (DMSO-d₆).




Figure Annex B.14. ¹³C NMR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (**4m**) compound (DMSO-d₆).




Figure Annex B.15. ^{13}C NMR spectra for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (**4n**) compound (DMSO-d_6).



**ADDITIONAL EXPLANATIONS C
COMPOUNDS' FT-IR SPECTRA**




Figure Annex C.1. IR spectra for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (**2**) compound.




Figure Annex C.2. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)benzamide (**4a**) compound.




Figure Annex C.3. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (**4b**) compound.




Figure Annex C.4. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio) benzamide (**4c**) compound.




Figure Annex C.5. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichlorobenzamide (**4d**) compound.




Figure Annex C.6. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluorobenzamide (**4e**) compound.




Figure Annex C.7. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (**4f**) compound.




Figure Annex C.8. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (**4g**) compound.




Figure Annex C.9. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluorobenzamide (**4h**) compound.




Figure Annex C.10. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichloro benzamide (**4i**) compound.




Figure Annex C.11. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (**4j**) compound.




Figure Annex C.12. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl) benzamide (**4k**) compound.




Figure Annex C.13. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (**4l**) compound.




Figure Annex C.14. IR spectra for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (**4m**) compound.




Figure Annex C.15. IR spectra for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (**4n**) compound.



**ADDITIONAL EXPLANATIONS D
COMPOUNDS' MS SPECTRA**




Figure Annex D.1. Mass spectrum for 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-amine (**2**) compound.




Figure Annex D.2. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)benzamide (**4a**) compound.




Figure Annex D.3. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-nitrobenzamide (**4b**) compound.




Figure Annex D.4. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(methylthio) benzamide (**4c**) compound.




Figure Annex D.5. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dichlorobenzamide (**4d**) compound.




Figure Annex D.6. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-difluorobenzamide (**4e**) compound.




Figure Annex D.7. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,4-dimethoxy benzamide (**4f**) compound.




Figure Annex D.8. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dimethoxy benzamide (**4g**) compound.




Figure Annex D.9. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-difluorobenzamide (**4h**) compound.




Figure Annex D.10. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-3,5-dichlorobenzamide (**4i**) compound.




Figure Annex D.11. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-ethylbenzamide (**4j**) compound.




Figure Annex D.12. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-(trifluoromethyl) benzamide (**4k**) compound.




Figure Annex D.13. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)-4-cyanobenzamide (**4l**) compound.




Figure Annex D.14. Mass spectrum for N-(5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-yl)acetamide (**4m**) compound.




Figure Annex D.15. Mass spectrum for Ethyl 5-(2,6-dichlorobenzyl)-1,3,4-thiadiazole-2-ylcarbamate (4n) compound.

REFERENCES

- [1] Nelson J. A., Rose L. M. and Bennett L.L., "Effect of 2-amino-1,3,4-thiadiazole on Ribonucleotide Pools of Leukemia L1210 Cells" *Cancer Research*, 36: 1375-1378 (1976).
- [2] Gulerman, N., Rollas, S., Ulgen, M. and Gorrod, J. W., "Synthesis and evaluation of some substituted 1,3,4-thiadiazole derivatives", *Boll Chim. Farmaceutico-Anno*, 7: 375-379 (1995).
- [3] Pulvermacher, G., "Ueber einige akommlinge des thiosemicarbazids und umsetzungproducte derselben", *Berlin*, 27: 613-630 (1894).
- [4] Partt, E. F. and Kamlet, M. M., "Reaction rates by distillation. IX the condensation of anilines with benzadeydes", *J. Org. Chem.*, 26: 4029-4032 (1961).
- [5] Freund, M. and Meinecke, C., "Ueber derivate des thiodiazolins" *Berlin*, 29: 2511-2517 (1896).
- [6] Marckwald, W. and Bott A., "Ueber das 1-Benzoyl-4-phenylthiosemica", *Berlin*, 29: 2914-2919 (1896).
- [7] Clark, J. H., English, J. P., Winnek, P. S., Marson, H. W., Cole, Q. P., and Clapp, J. W., "Studies in chemotherapy, XII. some sulfonilamido heterocycles" *J. Am. Chem. Soc.*, 68: 96-99 (1946).
- [8] Hoggarth, E., "Compounds related to thiosemicarbazide. Part II. 1-beyoylthiosemicarbazides", *J. Chem. Soc.*, 1163-1167 (1949).
- [9] Coburn, R. A., Bhoosman, B. and Glennon, R. A., "The preparation of 2-alkylamino-1,3,4-thiadiazoles", *J. Org. Chem.*, 38: 3947-3949 (1973).
- [10] Doğan, H. N., Duran, A., Rollas, S., Şener, G., Uysal, M. K. and Gülen, D., "Synthesis of new 2,5-disubstituted-1,3,4thiadiazoles and preliminary evaluation of anticonvulsant and antimicrobial activities", *Bioorg. Med. Chem.*, 10: 2893-2898 (2002).
- [11] Matysiak, J., "Evaluation of antiproliferative effect in vitro of some 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole derivatives", *Chem. Pharm. Bull.*, 54 (7): 988-991 (2006).
- [12] Wang, X., Li, Z. Da, Y. and Wei, B., "Microwave induced synthesis of 2-(2-furoylamido)- 5 -aryloxymethyl -1,3,4-thiadiazoles", *Synt. Commun.*, 31 (16): 2537-2541 (2001).

- [13] Foroumadi A, Mansouri S, Kiani Z, Rahmani A. Synthesis and invitro antibacterial evaluation of N-[5-(5-nitro-2-thionyl)-1,3,4-thiadiazole-2-yl]piperazinyl quinolones. *Eur J Med Chem*, 2003; 38: 851-854.
- [14] Young G., and Eyre W., "III-Oxidation of benzalthiosemicarbazone" *J. Chem. Soc. Trans*, 79: 54-60 (1901).
- [15] Schenone, S. Brullo, C. Bruno, O. Bondavalli, F. Ranise, A. Flippeli, W. Rinaldi, B. Capuano, A. and Falcone, G., "New 1,3,4-thiadiazole derivatives and owed with analgesic and anti-inflammatory activities", *Bioorg. Med. Chem.*, 14: 1698-1705 (2006).
- [16] Shafiee, A. Naimi, E. Maansobi, P. Foroumadi, A. and Shekari, M., "Syntheses of substituted-oxazoli-1,3,4-thiadiazoles and 1,2,4-triazoles", *J. Heterocyclic Chem.*, 32: 1235-1239 (1995).
- [17] Rollas, S., "Reductive cleavage of azo compounds with hydrazine hydrate and some new 1,3,4-thiadiazoles derivatives", *J. Pharm. Marmara Üniversitesi*, 1: (12): 59-68 (1985).
- [18] Huisgen, R. Sturn, H. J. and Seidel, M., *Chem. Ber.*, 94: 1555 (Chem Abs. 55/23537a) (1961).
- [19] Kurzer, F., "Thiadiazoles part XI. Synthesis and cyclization of N-(thiobenzamido) guanides and related compounds", *J. Chem. Soc.*, 1617-1625 (1961).
- [20] Efimova, Y. A. and Karabanovich, G. G. and Artamonova, T. V. and Koldobskii, G. I., "Microwave-assisted synthesis of 2-aryl(hetaryl)-5-phenylamino-1,3,4-thiadiazoles from 5-substituted tetrazoles", *Russ. J. Org. Chem.*, 45 (4): 631-632 (2009).
- [21] El-Rahman, N. M. A. Saleh, T. S. and Mady, M. F., "Ultrasound assisted synthesis of some new 1,3,4-thiadiazole and bi (1,3,4-thiadiazole) derivates incorporating pyrazolone moeity", *Ultrason Sonochem*, 16: 70-74 (2009).
- [22] Raj MM, Patel HV, Raj LM, Patel NK. Synthesis and biological evaluation of some new 1, 3, 4- thiadiazole derivatives for their antimicrobial activities. *Int J Pharm Chem Biol Sci* 2013; 3(3):814-820.
- [23] Kumar A, Amir M, Ali I, Khan SA. Synthesis of Pharmaceutically important 1, 3, 4- thiadiazole and imidazolinone derivatives as antimicrobials. *Indian J Chem* 2009; 4813: 1288-1293.
- [24] Sherman, W. R., "5-nitro-2-furyl-substituted-1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,3,5-triazines", *Org. Chem.*, 26: 88-95 (1961).

- [25] Mishra, H. K., "Synthesis of some new substituted 1,3,4 oxadiazoles as potential insecticidal, antibacterial and anti-acetylcholine esterase agents", *Arch. Pharm. Weinheim*, 316 (6): 487-493 (1983).
- [26] Asato, G. and Berkelhammer, G., "Nitroheterocyclic antimicrobial agents, 1-methyl-2-nitro-5-imidazolyl derivatives", *J. Med. Chem.*, 15 (10): 1086-1088 (1972).
- [27] Gawende, N. G. and Shingare, M. S., "Synthesis of some thiazolyl-thiosemicarbazides, triazoles, oxadiazoles, thiadiazoles and their microbial activity", *Ind. J. Chem.*, 26 (B): 387-389 (1987).
- [28] Patel, H. V. and Fernandes, P. S., "Synthesis and biological activities of some substituted pyrazolylmethylene-1,2,4-triazoles, 1,3,4-thiadiazoles", *J. Ind. Chem. Soc.*, 67: 401-403 (1990).
- [29] Terzioğlu, N. Karalı, N. Gürsoy, A. Ötük, G. Kiraz, M. Erturan, Z., "Synthesis and antimicrobial activity of new triazole and thiadiazole derivatives of 4(3*H*)-quinazolinones", *Acta Pharm. Turcica*, 40 (2): 77-82 (1998).
- [30] Ashour, F. A. Habib, N. S. El-Taibbi, M. El-Dine, S. El Dine, A. S., "Synthesis of 1,3,4-thiadiazoles, imidazol[2,1-*b*]1,3,4 thiadiazoles and thiadiazolo 3,2-*a*] pyrimidines derived from benzimidazole as potential antimicrobial agents", *II Farmaco*, 45 (12): 1341-1349 (1990).
- [31] Gülerman, N. N. Rollas, S. Erdeniz, H. and Kiraz, M., "Antibacterial antifungal and antimicrobacterial activities of some substituted thiosemicarbazides and 2,5-disubstituted-1,3,4-thiadiazoles", *FABAD J. Pharm. Science*, 25: 1-5 (2001).
- [32] Reddy, K. R. Mogilaiah, K. Swamy, B. and Sreenivasulu, B., "Synthesis of some 1,8-naphthyridinylthiosemicarbazides, triazoles and thiadiazoles", *Acta Chimica Hungaricae*, 127 (1): 45-50 (1990).
- [33] Rollas, S. Karakuş, S. Barlas-Durgun, B. Kiraz, M. and Erdeniz, H., "Syntheses and antimicrobial activity of some 1,4-disubstituted thiosemicarbazide and 2,5-disubstituted-1,3,4-thiadiazole derivatives", *II Farmaco*, 51 (12): 811-814 (1996).
- [34] Tsotinis, A. Varvaresou, A. Calogeropoulou, T. Siatra-Papastaikoudi, T. and Tiligada, A., "Synthesis and antimicrobial evaluation indole containing derivatives of 1,3,4-thiadiazole, 1,2,4-triazole and their open chain counterparts", *Arzneim.-Forsch./Drug Res.*, 47 (1): 307-310 (1997).
- [35] Labanauskas, L. Kalkas, V. Udrenaite, E. Gaidelis, P. Brukstus, A. and Dauksas, V., "Synthesis of 3-(3,4-dimethoxyphenyl)-1,3,4-thiazole derivatives exhibiting antiinflammatory activity", *Pharmazie*, 56 (8) 617-619 (2001).

- [36] Mullican, M. D. Wilson M. W. Connor, D. T. Kastlan, C. R. Schrier, D. J. and Dyer, R. D., “ Design of 5-(3,5-dii-tert-butyl-4-hydroxyphenyl) -1,3,4-thiadiazoles, -1,3,4-oxadiazoles and 1,2,4-triazoles as orally-active nonulcerogenic antiinflammatory agents”, *J. Med.Chem.*, 36 (8): 1090-1099 (1993).
- [37] Sharma, S. Srivastava, V. K. and Kumar, A., “Newer N-substitued anthranilic acid derivatives as potent anti-inflammatory agents”, *Euro. J. Med. Chem.*, 37 (8): 689-697 (2002).
- [38] Guptha SK, Sharma PK. Synthesis and anti-inflammatory activity of disubstituted 1,3,4- thiadiazole. *Int J Drug Formulation Res* 2011; 2(2): 344-350.
- [39] Foroumadi, A. Tabatabai, S. A. Gitinezhad, G. Zarrindast, M. R., and Shafiee, A., “Synthesis and anticonvulsant activity of 5-aryl-1,3,4-thiadiazole derivatives”, *Pharm. Pharmacol. Commun.*, 6: 31 31-33 (2000).
- [40] Chimmiri, A. Grasso, S. and Monforte, A. M. and Zappala, M., “Synthesis and anticonvulsant properties of 3-(1,3,4-thiadiazolidin)-4-ones”, *II Farmaco*, 46 (7,8): 935-943 (1991).
- [41] Masi HH, Gajjor AK, Savjani JK, Masi Inayal. Synthesis and anticonvulsant activity of novel 2,5-disubstituted 1, 3, 4- thiadiazole derivatives. *Int J Pharmtech Res* 2011; 3(4): 2017-2024.
- [42] Stilling, M. R. Welbourn, A. P. and Walter, D. S., “Substitued 1,3,4-Thiadiazoles with anticonvulsant activity, 2. aminoalkyl dervatives”, *J. Med. Chem.*, 29 (11): 2280-2284 (1986).
- [43] Chapleo, C. B. Myers, P. L. Smith, A. C. Stilling, M. R. Tulloch, I. F. and Walter, D. S., “Substitued 1,3,4-thiadiazoles with anticonvulsant activity, 4. amidines”, *J. Med. Chem.*, 31 (1): 7-11 (1988).
- [44] Chapleo, C. B. Myers, M. Meyers, P. L. Saville, J. F. Smith, A. C. B. Stilling, M. R. Tulloch, I. F. Walter, D. S. and Welbourn, A. P., “Substitued 1,3,4-thiadiazoles with anticonvulsant activity, 1-Hydrazines”, *J. Med. Chem.*, 29: 2273-2280 (1986).
- [45] Vio, L. and Mamolo, M. G. and Laneve, A., “Synthesis and antihypertensive activity of some 1,3,4-thiadiazole derivatives”, *II Farmaco*, 44: 165-172 (1988).
- [46] Karakuş, S. and Rollas, S., “Synthesis and antituberculosis activity of new N-phenyl-N’-[4-(5-alkyl/arylamino-1,3,-thiadiazole-2-yl) phenyl) thioüreas”, *II Farmaco*, 57 (7): 577-581 (2002).
- [47] Karigar AA, Himaja M, Male SV, Prathap KJ, Sikarwar MS. One pot synthesis and antitubercular activity of 2-amino -5-aryl -5H thiazolo [4,3-b]-1, 3, 4-thiadiazoles. *Int Res J Pharm* 2011; 2(1): 153-158.

- [48] Datar PA, Deokule TA. Design and synthesis of thiadiazole derivatives as antidiabetic agents. *Med Chem* 2014; 4(4): 390-399.
- [49] Hanna, M. A. Girges M. M. Rasadala, D. Gawinecki, R., "Synthesis and pharmacological evaluation of some novel 5-(pyrazol-3-yl) thiadiazole and oxadiazole derivatives as potential hypoglycemic agents", *Arzneim.-Forsch./Drug Res.*, 45 (II): 1074-1078 (1995).
- [50] Mhasalkar, M. Y. Shah, M. H. Pilankar, P. D. Nilkam, S. T. Anantanarayanan, K.G. and Deliwala, C. V., "Synthesis and hypoglycemic activity of 3-aryl (or pyridyl)-5-alkyl(or aryl)amino-1,3,4-thiadiazoles and some sulfonylurea derivatives of 4H-1,2,4-triazoles", *J. Med. Chem.*, 14 (10): 1000-1003 (1971).
- [51] Naskar A, Singha T, Guria T, Singh J, Kumar AB, Maity TK. Synthesis, characterization and evaluation of anticancer activity of some new schiff bases of 1, 3, 4-thiadiazole derivatives. *Int J Pharmacy Pharm Sci* 2015; 7(3): 397-402.
- [52] Chou, J. Y. Lai, S. Y. Pan, S. L. Jow, G. M. Chern, J. W. and Guh, J. H., "Investigation of anticancer mechanism of thiadiazole based compound in human non-small cell lung cancer A549 cells", *Biochem. Pharmacol.*, 66 (1): 115-124 (2003).
- [53] Banerjee S, Swaroop TVSS, Ferdy IC, Singh A, lakshmi SM, Dr. Mohan, Dr. Saravunan *J. Indo Am J Pharm Res* 2014; 2(2): 1074-1082.
- [54] Sancak, K. Er, M., and Ünver, Y., "Synthesis of 2-acylamino, 2-arylamino and ethoxycarbonylimino-1,3,4-thiadiazoles as antitumor agents", *Türk J. Chem.*, (TÜBİTAK), 31: 125-134 (2007).
- [55] Miyamoto, K. Koshiura, R. Mori, M. Yokoi, H. Mori, C. Hasegawa, T. and Takatori, K., "Antitumor activity of 5-substituted 2-acylamino-1,3,4-thiadiazoles against transplantable rodent tumors", *Chem. Pharm. Bull.*, 33 (11): 5126-5129 (1985).
- [56] Bahadur, S. Singh, S. P. and Shukla, M. K., "Synthesis of somethiosemicarbazides, thiadiazoles, triazoles and their derivatives as potential antiviral agents", *Arch. Pharma. Weinheim*, 315: 312-317 (1982).
- [57] Mazzone, G. Pignatello, R. Mazzone, S. Panico, A. Pennisi, G. Castana, R. and Mazzone, P., "Synthesis and local anesthetic activity of alkylaminocyl derivatives of 2-amino-1,3,4-thiadiazoles", *II Farmaco*, 48 (9): 1207-122 (1993).
- [58] Habib, N. S. İsmil, K. A. El-Tombary, A. A. and Abdel A. T., "Part IV: Synthesis and antilipidemic testing of heterocyclic derivatives of hexadecyl and cyclohexyl hemisuccinate esters", *Pharmazie*, 55 (7): 495-499 (2000).

- [59] Er M, Isildak G, Tahtaci H, and Karakurt T., “Novel 2-amino-1,3,4-thiadiazoles and their acyl derivatives: Synthesis, structural characterization, molecular docking studies and comparison of experimental and computational results” *J Mol Struct*, 1110:102–113 (2016).



RESUME

Ali Hasin BAWAH was born in Misurata –Libya in 1969 and he graduated first and elementary education in this city.He completed high school education in Misurata high school, after that, he started undergraduate program in Misurata University Department of chemistry in 1991.Then in 2015, he started assignment as a Research Assistant in Karabuk University Department of Chemistry.To complete M. Sc. Education, he moved to Karabuk University, where he has been still working as a R. A. for.

CONTACT INFORMATION

Adress: Karabuk University
Graduate School of Natural &Applied Science
Demir-Celik Campus/KARABUK

E-mail: ahmbn2007@gmail.com